RGD DISEASE ONTOLOGY - ANNOTATIONS |
|
RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.
|
Term: | hepatocellular carcinoma |
|
Accession: | DOID:684
|
browse the term
|
Definition: | A liver carcinoma that has_material_basis_in undifferentiated hepatocytes and located_in the liver. (DO) |
Synonyms: | exact_synonym: | Childhood Hepatocellular Carcinoma; HCC; Hepatocellular Cancer; Hepatocellular Carcinoma, Childhood Type, Somatic; LCC; adult liver cancer; adult liver cancers; hepatocellular cancers; hepatocellular carcinomas; hepatoma; hepatomas; liver cell carcinoma; liver cell carcinomas |
| narrow_synonym: | HEPATOBLASTOMA; HEPATOBLASTOMA CAUSED BY SOMATIC MUTATION; hepatitis B virus induced hepatocellular carcinoma; hepatitis C virus induced hepatocellular carcinoma; hepatitis virus-related hepatocellular carcinoma |
| primary_id: | MESH:D006528 |
| alt_id: | OMIM:114550 |
| xref: | EFO:0000182; EFO:0000189; EFO:0008503; EFO:0008504; EFO:0008505; ICD-O:M8170/3; NCI:C129298; NCI:C24029; NCI:C3099; NCI:C38756; NCI:C60416; ORDO:88673 |
For additional species annotation, visit the
Alliance of Genome Resources.
|
|
|
|
G |
A2m |
alpha-2-macroglobulin |
|
IEP ISO |
mRNA,protein:increased expression:liver: CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:15509519 PMID:15509519 |
RGD:1358261 |
NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
|
|
G |
Aadat |
aminoadipate aminotransferase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr16:29,509,392...29,544,332
Ensembl chr16:29,509,394...29,544,332
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
severity |
IEP ISO |
mRNA:decreased expression:liver (human) |
RGD |
PMID:16941710 PMID:30580964 |
RGD:1598532, RGD:24922199 |
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
susceptibility |
IEP ISO |
DNA:polymorphism: :c.3751G>A(human) DNA:polymorphism: : c.1465C > T(human) CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:17510421 PMID:25625052 PMID:24175826 PMID:23488625 |
RGD:11041138, RGD:14700905, RGD:14700904 |
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
|
ISO ISS |
CTD Direct Evidence: marker/mechanism OMIM:114550 |
CTD MouseDO |
PMID:22022477 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
|
IEP |
mRNA:increased expression:liver |
RGD |
PMID:25842354 |
RGD:11535155 |
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abce1 |
ATP binding cassette subfamily E member 1 |
|
ISO |
mRNA:increased expression:liver (human) |
RGD |
PMID:21932399 |
RGD:11041873 |
NCBI chr19:28,205,566...28,230,489
Ensembl chr19:28,205,555...28,230,489
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
|
ISO |
|
RGD |
PMID:32171747 |
RGD:126907997 |
NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21147110 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Ace |
angiotensin I converting enzyme |
susceptibility |
ISO |
CTD Direct Evidence: therapeutic DNA:insertion/deletion:intron 16: |
CTD RGD |
PMID:16328049 PMID:25208933 |
RGD:11343535 |
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Acer3 |
alkaline ceramidase 3 |
disease_progression |
ISO |
|
RGD |
PMID:30097213 |
RGD:35673325 |
NCBI chr 1:152,504,180...152,606,596
Ensembl chr 1:152,504,186...152,606,591
|
|
G |
Acly |
ATP citrate lyase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21147110 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Aco2 |
aconitase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21472284 |
|
NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12771043 PMID:15565109 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19363144 |
|
NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427
|
|
G |
Actb |
actin, beta |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19363144 PMID:21472284 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19514085 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adamts13 |
ADAM metallopeptidase with thrombospondin type 1 motif, 13 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 3:10,299,264...10,338,464
Ensembl chr 3:10,300,028...10,346,687
|
|
G |
Add1 |
adducin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19363144 |
|
NCBI chr14:76,108,643...76,167,267
Ensembl chr14:76,108,654...76,167,182
|
|
G |
Adgrg7 |
adhesion G protein-coupled receptor G7 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr11:43,808,101...43,877,539
Ensembl chr11:43,813,801...43,876,316
|
|
G |
Adh4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
susceptibility |
ISO |
DNA:SNP:intron:+276T>G (rs1501299) (human) |
RGD |
PMID:23740135 |
RGD:14401720 |
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500
|
|
G |
Adra2b |
adrenoceptor alpha 2B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 3:114,585,174...114,589,220
Ensembl chr 3:114,585,169...114,589,355
|
|
G |
Afp |
alpha-fetoprotein |
severity treatment disease_progression |
ISO IEP |
protein:increased expression:serum (human) CTD Direct Evidence: marker/mechanism associated with hepatitis B |
CTD RGD |
PMID:9029167 PMID:15276417 PMID:24012840 PMID:28284560 PMID:32961231 PMID:22147961 PMID:25999787 PMID:22392353 PMID:25968302 PMID:28611981 More...
|
RGD:14401581, RGD:152177911, RGD:125097525, RGD:126790583, RGD:126790579 |
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Aicda |
activation-induced cytidine deaminase |
|
ISO |
|
RGD |
PMID:18997814 |
RGD:127285629 |
NCBI chr 4:155,774,132...155,783,972
Ensembl chr 4:155,774,132...155,783,972
|
|
G |
Ak3 |
adenylate kinase 3 |
|
ISO |
protein:decreased expression:liver |
RGD |
PMID:17203974 |
RGD:13842477 |
NCBI chr 1:226,737,472...226,764,647
Ensembl chr 1:226,739,318...226,764,625
|
|
G |
Akr1a1 |
aldo-keto reductase family 1 member A1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32805337 |
|
NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
|
ISO IEP |
protein:increased expression:liver (human) protein:increased expression:liver (rat) |
RGD |
PMID:19422879 PMID:21683810 |
RGD:8548685, RGD:5509919 |
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21472284 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21472284 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
treatment |
ISO IEP |
CTD Direct Evidence: marker/mechanism ClinVar Annotator: match by term: Hepatocellular cancer |
CTD ClinVar RGD |
PMID:17611497 PMID:18256540 PMID:18392055 PMID:18504432 PMID:18611285 PMID:18954143 PMID:19418217 PMID:19487299 PMID:19853286 PMID:20233444 PMID:20453058 PMID:21464312 PMID:21512767 PMID:21793738 PMID:22538770 PMID:22610119 PMID:22722201 PMID:22722839 PMID:22980975 PMID:23237847 PMID:23348505 PMID:23700467 PMID:23728071 PMID:23934607 PMID:24190505 PMID:24657128 PMID:25157968 PMID:26619011 PMID:28492532 PMID:32045588 PMID:25999787 PMID:31801250 More...
|
RGD:152177911, RGD:151893509 |
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
|
IEP ISO |
protein:increased phosphorylation:liver cancer cell (rat) protein:increased phosphorylation:liver (mouse) |
RGD |
PMID:19309364 PMID:28100771 |
RGD:2313299, RGD:127285675 |
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Alb |
albumin |
susceptibility |
ISO |
protein:decreased expression:serum (human) associated with hepatitis C;protein:decreased expression:serum |
RGD |
PMID:23892757 PMID:22392353 PMID:29040987 |
RGD:11035269, RGD:125097525, RGD:14694841 |
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
susceptibility no_association severity |
ISO |
associated with alcoholic liver cirrhosis;DNA:missense mutation:cds:p.E487K (human) associated with alcohol use disorder;DNA:missense mutation:cds: (human) DNA:missense mutation:exon 12: (human) associated with hepatitis B;DNA;missense mutation, haplotype:cds: (rs671) (human) DNA:missense mutation:cds: (rs671) (human) mRNA, protein:decreased expression:liver (human) protein:decreased expression: liver (human) associated with hepatitis C:DNA:SNP:exon 12 (human) DNA:missense mutation:cds, exon 12:p.E487K (human) |
RGD |
PMID:25778454 PMID:18439068 PMID:10737710 PMID:26827895 PMID:29765251 PMID:28027570 PMID:26150517 PMID:12940444 PMID:1916152 More...
|
RGD:11054822, RGD:15042862, RGD:15042859, RGD:15042857, RGD:14700899, RGD:15036809, RGD:14696779, RGD:14696778, RGD:14696699 |
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Aldh7a1 |
aldehyde dehydrogenase 7 family, member A1 |
severity |
ISO |
mRNA:altered expression:liver tumor (human) |
RGD |
PMID:30901224 |
RGD:152995286 |
NCBI chr18:50,003,242...50,042,193
Ensembl chr18:50,009,934...50,042,193
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
|
IEP |
mRNA:increased expression:liver |
RGD |
PMID:3830170 |
RGD:2301136 |
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Alx4 |
ALX homeobox 4 |
ameliorates |
ISO IEP |
mRNA, protein:decreased expression:liver |
RGD |
PMID:28081728 PMID:31132711 PMID:31132711 |
RGD:153323329, RGD:153323330, RGD:153323330 |
NCBI chr 3:79,611,682...79,648,260
Ensembl chr 3:79,611,719...79,648,260
|
|
G |
Angptl6 |
angiopoietin-like 6 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 8:19,413,617...19,419,925
Ensembl chr 8:19,413,619...19,419,925
|
|
G |
Ank3 |
ankyrin 3 |
|
ISO |
protein:decreased expression:liver |
RGD |
PMID:26652480 |
RGD:153344559 |
NCBI chr20:18,602,267...19,225,831
Ensembl chr20:18,602,786...19,086,300
|
|
G |
Anln |
anillin, actin binding protein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 8:20,858,227...20,921,602
Ensembl chr 8:20,858,228...20,921,538
|
|
G |
Antxr1 |
ANTXR cell adhesion molecule 1 |
treatment |
ISO |
|
RGD |
PMID:20650339 |
RGD:9684932 |
NCBI chr 4:119,590,770...119,778,232
Ensembl chr 4:119,590,771...119,778,232
|
|
G |
Anxa10 |
annexin A10 |
disease_progression |
ISO |
mRNA:decreased expression:liver (human) |
RGD |
PMID:35693827 |
RGD:153344586 |
NCBI chr16:27,738,712...27,805,648
Ensembl chr16:27,738,712...27,805,648
|
|
G |
Anxa2 |
annexin A2 |
|
ISO |
mRNA, protein:increased expression:liver (human) |
RGD |
PMID:33675609 |
RGD:152999436 |
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Anxa4 |
annexin A4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21472284 |
|
NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
|
|
G |
Anxa6 |
annexin A6 |
disease_progression |
ISO |
associated with tumor vascularization; protein:decreased expression:liver tumor (human) |
RGD |
PMID:30901224 |
RGD:152995286 |
NCBI chr10:39,101,395...39,156,483
Ensembl chr10:39,097,109...39,156,433
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
|
ISO ISS |
ClinVar Annotator: match by term: Hepatocellular carcinoma OMIM:114550 CTD Direct Evidence: marker/mechanism ClinVar Annotator: match by term: Hepatocellular cancer | ClinVar Annotator: match by term: Hepatocellular carcinoma DNA:hypermethylation |
OMIM ClinVar MouseDO CTD RGD |
PMID:1316610 PMID:8381579 PMID:9824584 PMID:11466687 PMID:15311282 PMID:17293347 PMID:22135120 PMID:24728327 PMID:25479140 PMID:25741868 PMID:26467025 PMID:26530882 PMID:27081525 PMID:28135048 PMID:28195569 PMID:28492532 PMID:32390703 PMID:28203651 More...
|
RGD:14402050 |
NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696
|
|
G |
Apcs |
amyloid P component, serum |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19363144 |
|
NCBI chr13:85,373,219...85,374,195
Ensembl chr13:85,373,220...85,374,298
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
treatment |
ISO IEP |
CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:25109342 PMID:33841550 |
RGD:152998960 |
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Apln |
apelin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr X:127,180,801...127,213,567
Ensembl chr X:127,203,823...127,213,391
|
|
G |
Apoa1 |
apolipoprotein A1 |
disease_progression |
ISO |
CTD Direct Evidence: marker/mechanism associated with hepatitis B; protein:decreased expression:plasma (human) |
CTD RGD |
PMID:21472284 PMID:31211449 PMID:23935864 |
RGD:153350082, RGD:25671438 |
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoa2 |
apolipoprotein A2 |
|
ISO |
associated with hepatitis B; mRNA:increased expression:liver |
RGD |
PMID:31211449 |
RGD:153350082 |
NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
|
|
G |
Apoa4 |
apolipoprotein A4 |
disease_progression |
ISO |
associated with hepatitis B; |
RGD |
PMID:31211449 |
RGD:153350082 |
NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
|
|
G |
Apoc1 |
apolipoprotein C1 |
disease_progression |
ISO |
associated with hepatitis B; |
RGD |
PMID:31211449 |
RGD:153350082 |
NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375
|
|
G |
Apoc2 |
apolipoprotein C2 |
|
ISO |
associated with hepatitis B; mRNA:increased expression:liver |
RGD |
PMID:31211449 |
RGD:153350082 |
NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476
|
|
G |
Apoc3 |
apolipoprotein C3 |
susceptibility disease_progression |
ISO |
associated with Chronic Hepatitis B;DNA:SNP: :rs2854116(human) associated with hepatitis B; |
RGD |
PMID:27547913 PMID:31211449 |
RGD:153344620, RGD:153350082 |
NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583
|
|
G |
Apoc4 |
apolipoprotein C4 |
disease_progression |
ISO |
associated with hepatitis B; |
RGD |
PMID:31211449 |
RGD:153350082 |
NCBI chr 1:79,335,745...79,339,942
Ensembl chr 1:79,335,745...79,339,981
|
|
G |
Apoe |
apolipoprotein E |
|
ISO |
protein:increased expression:liver, serum (mouse) |
RGD |
PMID:21644509 |
RGD:6903288 |
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Apof |
apolipoprotein F |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 7:700,688...702,130
Ensembl chr 7:700,762...701,946
|
|
G |
Aprt |
adenine phosphoribosyl transferase |
|
IEP |
protein:increased activity:hepatoma (rat) |
RGD |
PMID:6327016 |
RGD:5135035 |
NCBI chr19:50,626,201...50,628,491
Ensembl chr19:50,626,202...50,628,431
|
|
G |
Ar |
androgen receptor |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:18639551 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arg1 |
arginase 1 |
disease_progression |
ISO |
associated with tumor vascularization; mRNA,protein:decreased expression:liver tumor (human) |
RGD |
PMID:17210712 PMID:30901224 |
RGD:4140476, RGD:152995286 |
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Arhgap11a |
Rho GTPase activating protein 11A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 3:100,590,865...100,607,146
Ensembl chr 3:100,590,865...100,607,559
|
|
G |
Arhgef39 |
Rho guanine nucleotide exchange factor 39 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 5:57,752,509...57,756,079
Ensembl chr 5:57,752,509...57,756,109
|
|
G |
Arid1a |
AT-rich interaction domain 1A |
exacerbates treatment |
ISO |
CTD Direct Evidence: marker/mechanism human gene in mouse model associated with non-alcoholic steatohepatitis mRNA, protein:decreased expression:liver (human) mRNA, protein:increased expression:liver (human) |
CTD RGD |
PMID:22561517 PMID:22634756 PMID:22922871 PMID:29136504 PMID:29136504 PMID:26569409 PMID:29113912 PMID:25975202 PMID:26589513 More...
|
RGD:126790634, RGD:126790634, RGD:11344640, RGD:125097519, RGD:125097495, RGD:125097485 |
NCBI chr 5:145,908,173...145,981,552
Ensembl chr 5:145,908,181...145,985,564
|
|
G |
Arid1b |
AT-rich interaction domain 1B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22634756 |
|
NCBI chr 1:45,567,991...45,923,644
Ensembl chr 1:45,563,623...45,923,493
|
|
G |
Arid2 |
AT-rich interaction domain 2 |
disease_progression exacerbates |
ISO |
CTD Direct Evidence: marker/mechanism associated with hepatitis B;protein:decreased expression:liver |
CTD RGD |
PMID:21822264 PMID:22634756 PMID:25701229 PMID:28498550 PMID:27351279 PMID:32071245 More...
|
RGD:150429631, RGD:150340712, RGD:150340711, RGD:150340708 |
NCBI chr 7:127,447,192...127,565,987
Ensembl chr 7:127,447,278...127,563,512
|
|
G |
Arid3a |
AT-rich interaction domain 3A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:35179300 |
|
NCBI chr 7:9,755,291...9,781,260
Ensembl chr 7:9,755,294...9,780,599
|
|
G |
Arrb2 |
arrestin, beta 2 |
treatment |
IEP |
|
RGD |
PMID:33841550 |
RGD:152998960 |
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Asf1b |
anti-silencing function 1B histone chaperone |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr19:24,181,024...24,195,604
Ensembl chr19:24,181,028...24,195,549
|
|
G |
Asl |
argininosuccinate lyase |
disease_progression |
ISO |
associated with tumor vascularization; mRNA,protein:decreased expression:liver tumor (human) |
RGD |
PMID:30901224 |
RGD:152995286 |
NCBI chr12:26,659,664...26,677,136
Ensembl chr12:26,659,565...26,679,662
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
|
IEP |
protein:increased activity:serum (rat) |
RGD |
PMID:10081 |
RGD:2316006 |
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Aspg |
asparaginase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 6:131,176,727...131,196,268
Ensembl chr 6:131,176,874...131,196,268
|
|
G |
Aspm |
assembly factor for spindle microtubules |
disease_progression |
ISO |
CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:28284560 PMID:18676753 |
RGD:13439743 |
NCBI chr13:51,074,849...51,123,755
Ensembl chr13:51,074,849...51,123,755
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
disease_progression |
ISO |
associated with tumor vascularization; mRNA,protein:decreased expression:liver tumor (human) |
RGD |
PMID:12359751 PMID:30901224 |
RGD:4140479, RGD:152995286 |
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atg101 |
autophagy related 101 |
disease_progression |
ISO |
|
RGD |
PMID:35592424 |
RGD:153350091 |
NCBI chr 7:132,398,477...132,407,643
Ensembl chr 7:132,398,483...132,407,633
|
|
G |
Atg7 |
autophagy related 7 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29191453 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Atm |
ATM serine/threonine kinase |
exacerbates |
ISO |
CTD Direct Evidence: marker/mechanism protein:increased expression:liver (human) |
CTD RGD |
PMID:12866955 PMID:19919837 |
RGD:126781750 |
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp5pb |
ATP synthase peripheral stalk-membrane subunit b |
|
ISO |
associated with hepatitis C |
RGD |
PMID:18932288 |
RGD:14696822 |
NCBI chr 2:193,424,138...193,435,418
Ensembl chr 2:193,424,047...193,435,418
|
|
G |
Atp5pd |
ATP synthase peripheral stalk subunit d |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21472284 |
|
NCBI chr10:100,657,700...100,662,960
Ensembl chr10:100,657,708...100,663,479
|
|
G |
Atp7b |
ATPase copper transporting beta |
onset |
IAGP |
|
RGD |
PMID:8291609 |
RGD:15036817 |
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Atp7bhts |
ATPase copper transporting beta; hepatitis |
onset |
IAGP |
|
RGD |
PMID:8291609 |
RGD:15036817 |
|
|
G |
Aurka |
aurora kinase A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
Aurkb |
aurora kinase B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Axin1 |
axin 1 |
disease_progression |
ISO |
ClinVar Annotator: match by term: Hepatocellular cancer | ClinVar Annotator: match by term: Hepatocellular carcinoma protein:decreased expression:liver (human) associated with Hepatitis B, Chronic,DNA:SNP, haplotype:exon:(rs1805105) T>C (human) CTD Direct Evidence: marker/mechanism |
ClinVar CTD OMIM RGD |
PMID:10700176 PMID:25741868 PMID:25822088 PMID:28492532 PMID:10700176 PMID:31514071 PMID:22960659 PMID:26968103 More...
|
RGD:1300371, RGD:150530482, RGD:150530481, RGD:14402039 |
NCBI chr10:15,163,477...15,215,615
Ensembl chr10:15,163,684...15,215,615
|
|
G |
Axin2 |
axin 2 |
|
ISO |
protein:increased expression:liver: |
RGD |
PMID:11809809 |
RGD:151356508 |
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
Azgp1 |
alpha-2-glycoprotein 1, zinc-binding |
disease_progression |
ISO IEP |
mRNA:decreased expression:liver |
RGD |
PMID:22625427 PMID:26902423 PMID:27993894 |
RGD:153350130, RGD:153350133, RGD:153350132 |
NCBI chr12:16,930,990...16,939,333
Ensembl chr12:16,931,024...16,939,091
|
|
G |
Azin1 |
antizyme inhibitor 1 |
disease_progression |
ISO |
RNA:increased editing:liver |
RGD |
PMID:23291631 |
RGD:14700705 |
NCBI chr 7:69,654,773...69,681,578
Ensembl chr 7:69,654,663...69,681,578
|
|
G |
Banf1 |
BAF nuclear assembly factor 1 |
treatment |
IEP ISO |
mRNA, protein:increased expression:liver (rat) mRNA, protein:increased expression:liver (human) |
RGD |
PMID:29059470 PMID:29059470 PMID:29059470 |
RGD:155791679, RGD:155791679, RGD:155791679 |
NCBI chr 1:202,672,170...202,674,215
Ensembl chr 1:202,671,305...202,674,188
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
treatment |
IEP |
|
RGD |
PMID:33841550 |
RGD:152998960 |
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
treatment |
ISO IEP |
mRNA:increased expression:liver (mouse) |
RGD |
PMID:28100771 PMID:33841550 |
RGD:127285675, RGD:152998960 |
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
treatment |
ISO IEP |
CTD Direct Evidence: marker/mechanism|therapeutic mRNA:increased expression:liver (mouse) |
CTD RGD |
PMID:10629087 PMID:11509945 PMID:33841550 PMID:28100771 |
RGD:152998960, RGD:127285675 |
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bco2 |
beta-carotene oxygenase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 8:50,882,174...50,907,676
Ensembl chr 8:50,882,181...50,915,467
|
|
G |
Bcorl1 |
BCL6 co-repressor-like 1 |
disease_progression |
ISO |
|
RGD |
PMID:29679906 PMID:26879601 |
RGD:150340705, RGD:11556159 |
NCBI chr X:127,516,504...127,584,529
Ensembl chr X:127,537,538...127,584,087
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
disease_progression |
ISO |
associated with tumor vascularization; mRNA,protein:decreased expression:liver tumor (human) |
RGD |
PMID:30901224 |
RGD:152995286 |
NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742
|
|
G |
Bhmt2 |
betaine-homocysteine S-methyltransferase 2 |
severity |
ISO |
mRNA:altered expression:liver tumor (human) |
RGD |
PMID:30901224 |
RGD:152995286 |
NCBI chr 2:24,895,525...24,912,475
Ensembl chr 2:24,895,533...24,912,475
|
|
G |
Bid |
BH3 interacting domain death agonist |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15289866 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
ameliorates treatment exacerbates |
ISO |
human cell line in a mouse model mRNA, protein:increased expression:liver (human) associated with hepatitis B;mRNA, protein:increased expression:liver (human) |
RGD |
PMID:30368883 PMID:30210622 PMID:33310033 PMID:22820591 PMID:22682366 |
RGD:152998937, RGD:152999010, RGD:152998988, RGD:152998986, RGD:152998984 |
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
disease_progression |
ISO |
CTD Direct Evidence: marker/mechanism|therapeutic mRNA:increased expression:liver (human) |
CTD RGD |
PMID:16086872 PMID:20514400 PMID:31964418 |
RGD:153344516 |
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Birc7 |
baculoviral IAP repeat-containing 7 |
exacerbates |
ISO |
mRNA:increased expression:liver (human) |
RGD |
PMID:31964418 |
RGD:153344516 |
NCBI chr 3:168,047,824...168,052,606
Ensembl chr 3:168,047,824...168,052,606
|
|
G |
Blzf1 |
basic leucine zipper nuclear factor 1 |
disease_progression |
ISO |
|
RGD |
PMID:26342799 |
RGD:14398326 |
NCBI chr13:76,641,757...76,656,977
Ensembl chr13:76,641,515...76,656,999
|
|
G |
Bmi1 |
BMI1 proto-oncogene, polycomb ring finger |
treatment |
ISO |
|
RGD |
PMID:26919246 |
RGD:14928318 |
NCBI chr17:81,332,175...81,341,625
Ensembl chr17:81,332,214...81,388,690
|
|
G |
Bmper |
BMP-binding endothelial regulator |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 8:21,732,225...21,977,261
Ensembl chr 8:21,732,225...21,977,256
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27222248 |
|
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
|
|
G |
Bsg |
basigin (Ok blood group) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:36574092 |
|
NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18393292 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650
|
|
G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547
|
|
G |
C3 |
complement C3 |
|
IEP |
|
RGD |
PMID:23245919 |
RGD:11040806 |
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
C6h14orf180 |
similar to human chromosome 14 open reading frame 180 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 6:131,557,193...131,568,245
Ensembl chr 6:131,559,690...131,567,342
|
|
G |
C9 |
complement C9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19363144 PMID:28284560 |
|
NCBI chr 2:55,573,094...55,621,345
Ensembl chr 2:55,572,992...55,621,338
|
|
G |
Cab39 |
calcium binding protein 39 |
disease_progression |
ISO |
|
RGD |
PMID:28605041 PMID:28605041 |
RGD:14398832, RGD:14398832 |
NCBI chr 9:86,463,095...86,524,545
Ensembl chr 9:86,463,095...86,524,544
|
|
G |
Cad |
carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase |
|
IEP IAGP |
mRNA:increased expression:liver DNA:amplification:cds (rat) |
RGD |
PMID:2888462 PMID:7053379 PMID:2914957 |
RGD:2303530, RGD:10755426, RGD:5132587 |
NCBI chr 6:25,292,133...25,315,078
Ensembl chr 6:25,292,133...25,319,861
|
|
G |
Cadm1 |
cell adhesion molecule 1 |
|
IEP |
DNA, mRNA, protein:hypermethylation, decreased expression:promoter:liver |
RGD |
PMID:17428255 |
RGD:2289095 |
NCBI chr 8:47,847,836...48,178,703
Ensembl chr 8:47,847,325...48,182,833
|
|
G |
Cadm2 |
cell adhesion molecule 2 |
disease_progression |
ISO |
mRNA, protein:decreased expression:liver |
RGD |
PMID:24240726 |
RGD:15092075 |
NCBI chr11:4,548,367...5,525,420
Ensembl chr11:4,555,159...5,525,400
|
|
G |
Calml3 |
calmodulin-like 3 |
severity |
ISO |
protein:decreased expression:liver (human) |
RGD |
PMID:29445139 |
RGD:151665319 |
NCBI chr17:66,419,844...66,423,083
Ensembl chr17:66,419,882...66,423,175
|
|
G |
Calr |
calreticulin |
exacerbates treatment |
ISO |
protein:increased expression:liver (human) human cells and recombinant gene in a mouse model |
RGD |
PMID:27055635 PMID:24997628 PMID:12096119 |
RGD:150521681, RGD:150521691, RGD:150521690 |
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Camk2n1 |
calcium/calmodulin-dependent protein kinase II inhibitor 1 |
|
ISO |
|
RGD |
PMID:23651211 |
RGD:18337283 |
NCBI chr 5:150,674,819...150,676,600
Ensembl chr 5:150,673,507...150,676,600
|
|
G |
Cap2 |
cyclase associated actin cytoskeleton regulatory protein 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr17:18,054,234...18,203,453
Ensembl chr17:18,054,431...18,203,373
|
|
G |
Capn3 |
calpain 3 |
|
IEP |
mRNA:decreased expression:skeletal muscle |
RGD |
PMID:10806331 |
RGD:1600777 |
NCBI chr 3:107,407,518...107,457,858
Ensembl chr 3:107,407,850...107,457,858
|
|
G |
Car12 |
carbonic anhydrase 12 |
disease_progression ameliorates |
ISO |
mRNA:altered expression:liver |
RGD |
PMID:35362480 PMID:29900055 PMID:31934040 PMID:35362480 |
RGD:153352325, RGD:155226869, RGD:153352328, RGD:153352325 |
NCBI chr 8:67,274,739...67,330,428
Ensembl chr 8:67,274,359...67,330,440
|
|
G |
Car2 |
carbonic anhydrase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21472284 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Car9 |
carbonic anhydrase 9 |
|
ISO |
mRNA:altered expression:liver |
RGD |
PMID:29900055 |
RGD:155226869 |
NCBI chr 5:57,763,234...57,769,838
Ensembl chr 5:57,763,206...57,769,838
|
|
G |
Carm1 |
coactivator-associated arginine methyltransferase 1 |
|
IEP |
mRNA,protein:increased expression:liver: |
RGD |
PMID:23912631 |
RGD:9586718 |
NCBI chr 8:20,097,262...20,141,950
Ensembl chr 8:20,097,254...20,147,689
|
|
G |
Casp3 |
caspase 3 |
treatment |
IEP |
|
RGD |
PMID:29133031 PMID:33841550 |
RGD:13782296, RGD:152998960 |
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
severity treatment |
ISO IEP |
CTD Direct Evidence: marker/mechanism associated with hepatitis B;DNA:insertion/deletion:promoter: (rs3834129) (human) |
OMIM CTD RGD |
PMID:28643196 PMID:29133031 |
RGD:14695027, RGD:13782296 |
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
treatment |
IEP |
|
RGD |
PMID:29133031 |
RGD:13782296 |
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
disease_progression |
ISO |
associated with liver cirrhosis with Hepatitis C;DNA:SNP:promoter:-262T>C (human) CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:33010264 PMID:21907168 |
RGD:27095879 |
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbfb |
core-binding factor subunit beta |
|
ISO |
mRNA:decreased expression:liver |
RGD |
PMID:17094378 |
RGD:126775147 |
NCBI chr19:33,049,162...33,092,752
Ensembl chr19:33,049,172...33,092,751
|
|
G |
Cbl |
Cbl proto-oncogene |
disease_progression |
ISO |
|
RGD |
PMID:26474280 |
RGD:11536137 |
NCBI chr 8:44,487,824...44,571,620
Ensembl chr 8:44,489,410...44,571,176
|
|
G |
Cbr1 |
carbonyl reductase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21056497 |
|
NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
|
|
G |
Cbx2 |
chromobox 2 |
disease_progression |
ISO |
mRNA:increased expression:liver (human) |
RGD |
PMID:35693827 |
RGD:153344586 |
NCBI chr10:104,278,517...104,287,384
Ensembl chr10:104,278,549...104,287,383
|
|
G |
Cbx4 |
chromobox 4 |
disease_progression |
ISO |
protein:increased expression:cytoplasm: |
RGD |
PMID:24838576 PMID:23943028 |
RGD:9586738, RGD:9586739 |
NCBI chr10:104,337,140...104,343,210
Ensembl chr10:104,336,876...104,356,706
|
|
G |
Cbx7 |
chromobox 7 |
|
ISO |
mRNA:decreased expression:liver |
RGD |
PMID:22041561 |
RGD:9587355 |
NCBI chr 7:111,460,656...111,479,231
Ensembl chr 7:111,460,656...111,477,973
|
|
G |
Ccbe1 |
collagen and calcium binding EGF domains 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr18:59,579,851...59,823,977
Ensembl chr18:59,580,768...59,824,400
|
|
G |
Ccl1 |
C-C motif chemokine ligand 1 |
|
ISO |
mRNA:increased expression:liver (mouse) |
RGD |
PMID:26569409 |
RGD:11344640 |
NCBI chr10:67,128,331...67,131,109
Ensembl chr10:67,128,331...67,131,159
|
|
G |
Ccl12 |
C-C motif chemokine ligand 12 |
|
ISO |
mRNA:increased expression:liver (mouse) |
RGD |
PMID:26569409 |
RGD:11344640 |
NCBI chr10:67,070,230...67,071,780
Ensembl chr10:67,070,230...67,071,780
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
treatment |
ISO |
RNA:increased expression:liver |
RGD |
PMID:27980102 PMID:22402625 PMID:12679798 PMID:27980102 |
RGD:14995459, RGD:14995927, RGD:14995468, RGD:14995459 |
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16284949 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
treatment susceptibility |
ISO |
associated with alcoholic liver cirrhosis;DNA:SNP:promoter:-403G>A(human) DNA:polymorphisms:promoter:-403G>A,-28C>G (human) |
RGD |
PMID:28011329 PMID:21610221 PMID:22374185 |
RGD:14995306, RGD:14995338, RGD:14995333 |
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccn1 |
cellular communication network factor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17699798 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccna1 |
cyclin A1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12029619 |
|
NCBI chr 2:139,231,738...139,278,066
Ensembl chr 2:139,201,074...139,243,157
|
|
G |
Ccnb1 |
cyclin B1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnb2 |
cyclin B2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Ccnd1 |
cyclin D1 |
susceptibility |
ISO |
CTD Direct Evidence: marker/mechanism mRNA:increased expression:liver (mouse) associated with Hepatitis B, Chronic;DNA:SNP:splice-site mutation:870G>A (human) |
CTD RGD |
PMID:12029619 PMID:19919837 PMID:22649188 PMID:25822088 PMID:26189965 PMID:28100771 PMID:25851350 More...
|
RGD:127285675, RGD:14401586 |
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
severity susceptibility disease_progression |
ISO |
associated with hepatitis B associated with Chronic Hepatitis C;DNA:SNP: :rs1049606(human) DNA:hypermethylation:CpG site |
RGD |
PMID:33320844 PMID:22004425 PMID:31059558 PMID:33320844 |
RGD:151664743, RGD:151665169, RGD:151665109, RGD:151664743 |
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccne1 |
cyclin E1 |
ameliorates |
IEP ISO |
CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:12029619 PMID:22634754 PMID:17196522 PMID:29551768 PMID:28100771 |
RGD:2289277, RGD:153297807, RGD:127285675 |
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccnf |
cyclin F |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101
|
|
G |
Ccng1 |
cyclin G1 |
severity treatment disease_progression |
IGI ISO IEP |
protein:decreased expression:liver (human) protein:increased expression:liver (human) human cells in mouse model |
RGD |
PMID:25431954 PMID:27982046 PMID:22835824 PMID:19584283 PMID:33543294 PMID:23804702 PMID:23804702 PMID:26345095 PMID:24034575 More...
|
RGD:151356922, RGD:151361200, RGD:151361198, RGD:151356981, RGD:151356970, RGD:151356967, RGD:151356967, RGD:151356933, RGD:151356932 |
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Ccng2 |
cyclin G2 |
|
ISO |
|
RGD |
PMID:27982046 |
RGD:151361200 |
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Ccr1 |
C-C motif chemokine receptor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16284949 |
|
NCBI chr 8:123,556,286...123,561,841
|
|
G |
Cd163 |
CD163 molecule |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878
|
|
G |
Cd274 |
CD274 molecule |
disease_progression |
ISO |
CTD Direct Evidence: marker/mechanism associated with hepatitis B associated with hepatitis B |
CTD RGD |
PMID:22396772 PMID:21912640 PMID:30267213 |
RGD:41410800, RGD:40818240 |
NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cd276 |
Cd276 molecule |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:16217749 |
|
NCBI chr 8:58,937,751...58,968,082
Ensembl chr 8:58,937,751...58,968,380
|
|
G |
Cd34 |
CD34 molecule |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr13:106,480,313...106,500,844
Ensembl chr13:106,480,043...106,499,832
|
|
G |
Cd40lg |
CD40 ligand |
|
ISO |
|
RGD |
PMID:19016771 |
RGD:2313413 |
NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306
|
|
G |
Cd5l |
Cd5 molecule-like |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 2:172,791,007...172,802,018
Ensembl chr 2:172,790,934...172,829,753
|
|
G |
Cd68 |
Cd68 molecule |
severity |
ISO |
protein:increased expression:liver (human) |
RGD |
PMID:28656201 |
RGD:40924686 |
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cdc20 |
cell division cycle 20 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdc25c |
cell division cycle 25C |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdc27 |
cell division cycle 27 |
|
ISO |
ClinVar Annotator: match by term: Hepatocellular cancer | ClinVar Annotator: match by term: Hepatocellular carcinoma |
ClinVar |
|
|
NCBI chr10:89,400,720...89,449,816
Ensembl chr10:89,400,940...89,449,736
|
|
G |
Cdc45 |
cell division cycle 45 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619
|
|
G |
Cdc6 |
cell division cycle 6 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cdca2 |
cell division cycle associated 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr15:41,895,946...41,942,226
Ensembl chr15:41,895,901...41,941,611
|
|
G |
Cdca3 |
cell division cycle associated 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 4:157,634,775...157,638,799
Ensembl chr 4:157,634,928...157,638,799
|
|
G |
Cdca5 |
cell division cycle associated 5 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 1:203,378,550...203,392,027
Ensembl chr 1:203,378,577...203,392,023
|
|
G |
Cdca8 |
cell division cycle associated 8 |
disease_progression |
ISO |
CTD Direct Evidence: marker/mechanism mRNA:increased expression:liver (human) |
CTD RGD |
PMID:28284560 PMID:35693827 |
RGD:153344586 |
NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629
|
|
G |
Cdh1 |
cadherin 1 |
severity |
IDA ISO |
DNA:hypermethylation protein:decreased expression:liver mRNA:increased expression:liver |
RGD |
PMID:17295234 PMID:18837082 PMID:24840851 PMID:30697077 PMID:30697077 |
RGD:2289638, RGD:14402047, RGD:14402046, RGD:14402045, RGD:14402045 |
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh13 |
cadherin 13 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18425332 PMID:18553387 PMID:28284560 |
|
NCBI chr19:46,349,562...47,387,462
Ensembl chr19:46,349,430...47,387,459
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
|
ISO |
protein:increased expression:liver (human) CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:28284560 PMID:19136513 |
RGD:2316317 |
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk12 |
cyclin-dependent kinase 12 |
exacerbates |
ISO |
mRNA, protein:increased expression:liver (human) |
RGD |
PMID:31519701 |
RGD:151361172 |
NCBI chr10:83,201,177...83,256,906
Ensembl chr10:83,201,211...83,280,888 Ensembl chr10:83,201,211...83,280,888
|
|
G |
Cdk13 |
cyclin-dependent kinase 13 |
onset |
ISO |
DNA:amplification: : |
RGD |
PMID:22912832 |
RGD:155641228 |
NCBI chr17:47,251,145...47,344,675
Ensembl chr17:47,251,163...47,341,721
|
|
G |
Cdk14 |
cyclin-dependent kinase 14 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22922871 |
|
NCBI chr 4:28,666,416...29,258,865
Ensembl chr 4:28,666,843...29,258,861
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
treatment |
ISO IEP |
CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:26189965 PMID:33841550 |
RGD:152998960 |
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
ISS |
OMIM:114550 |
MouseDO |
|
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20698225 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
severity |
ISO |
protein:decreased expression:liver (human) |
RGD |
PMID:26606000 |
RGD:11354707 |
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
severity |
IEP ISO IDA |
Protein:increased expression:liver ClinVar Annotator: match by term: Hepatocellular cancer | ClinVar Annotator: match by term: Hepatocellular carcinoma | ClinVar Annotator: match by term: LIVER CELL CARCINOMA CTD Direct Evidence: marker/mechanism Protein:decreased expression:liver DNA:hypermethylation:exon DNA:hypermethylation:promoter |
ClinVar CTD RGD |
PMID:7780957 PMID:8521414 PMID:9185756 PMID:9324288 PMID:10491434 PMID:14508519 PMID:16234564 PMID:16317707 PMID:16896043 PMID:21462282 PMID:25157968 PMID:25741868 PMID:25780468 PMID:25822088 PMID:26225579 PMID:26467025 PMID:26619011 PMID:28284560 PMID:28492532 PMID:33010264 PMID:35001868 PMID:16317707 PMID:11301474 PMID:12359353 More...
|
RGD:1600816, RGD:1600816, RGD:8552680, RGD:1600822 |
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn2a_v1 |
cyclin-dependent kinase inhibitor 2A, variant 1 |
|
IEP |
Protein:decreased expression:liver |
RGD |
PMID:16317707 |
RGD:1600816 |
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:33010264 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
treatment severity |
ISO |
CTD Direct Evidence: marker/mechanism associated with alcoholism; protein:increased expression:liver protein:decreased expression:liver mRNA:increased expression:liver |
CTD RGD |
PMID:28284560 PMID:23292002 PMID:23292002 PMID:27314282 PMID:22390936 |
RGD:15090802, RGD:15090802, RGD:15090801, RGD:15090800 |
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cdt1 |
chromatin licensing and DNA replication factor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16288022 PMID:21785164 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
|
ISO |
CTD Direct Evidence: marker/mechanism mRNA: increased expression:liver (human) |
CTD RGD |
PMID:14563831 PMID:30659195 |
RGD:40903042 |
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:14563831 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Celsr3 |
cadherin, EGF LAG seven-pass G-type receptor 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 8:109,530,597...109,558,360
Ensembl chr 8:109,530,641...109,558,354
|
|
G |
Cenpa |
centromere protein A |
|
ISO |
CTD Direct Evidence: marker/mechanism protein:increased expression:liver (human) |
CTD RGD |
PMID:28284560 PMID:21956590 |
RGD:36947377 |
NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675
|
|
G |
Cenpe |
centromere protein E |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 2:223,637,035...223,695,692
Ensembl chr 2:223,636,998...223,695,669
|
|
G |
Cenpf |
centromere protein F |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669
|
|
G |
Cenpm |
centromere protein M |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 7:113,748,026...113,759,296
Ensembl chr 7:113,747,516...113,764,258
|
|
G |
Cenpu |
centromere protein U |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr16:45,715,821...45,739,038
Ensembl chr16:45,714,294...45,738,823
|
|
G |
Cenpw |
centromere protein W |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 1:27,525,324...27,530,464
Ensembl chr 1:27,525,324...27,530,464
|
|
G |
Cep131 |
centrosomal protein 131 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr10:105,346,015...105,370,380
Ensembl chr10:105,346,015...105,370,380
|
|
G |
Cep164 |
centrosomal protein 164 |
susceptibility |
ISO |
associated with Chronic Hepatitis C;DNA:SNP: :rs573455 (human) |
RGD |
PMID:22004425 |
RGD:151665169 |
NCBI chr 8:46,070,901...46,134,511
Ensembl chr 8:46,071,076...46,134,336
|
|
G |
Cep55 |
centrosomal protein 55 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 1:235,832,823...235,848,401
Ensembl chr 1:235,832,878...235,848,394
|
|
G |
Ces1d |
carboxylesterase 1D |
disease_progression |
ISO |
protein:decreased expression:liver (human) associated with tumor vascularization; protein:decreased expression:liver tumor (human) mRNA, protein:decreased expression:liver tumor (human) |
RGD |
PMID:24259486 PMID:30901224 PMID:19658107 |
RGD:152995276, RGD:152995286, RGD:152995279 |
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Cfp |
complement factor properdin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr X:1,162,014...1,167,576
Ensembl chr X:1,161,979...1,167,573
|
|
G |
Chaf1b |
chromatin assembly factor 1 subunit B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr11:33,200,894...33,221,076
Ensembl chr11:33,200,981...33,221,070
|
|
G |
Chd4 |
chromodomain helicase DNA binding protein 4 |
exacerbates |
ISO |
mRNA:increased expression:liver (human) protein:increased expression:liver (human) |
RGD |
PMID:28486105 PMID:26095183 |
RGD:153323299, RGD:11571740 |
NCBI chr 4:157,898,503...157,931,632
Ensembl chr 4:157,899,391...157,931,541
|
|
G |
Chd5 |
chromodomain helicase DNA binding protein 5 |
|
ISO |
mRNA:decreased expression:liver |
RGD |
PMID:26517514 |
RGD:11537550 |
NCBI chr 5:162,848,273...162,898,997
Ensembl chr 5:162,848,394...162,896,291
|
|
G |
Ckap2l |
cytoskeleton associated protein 2-like |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 3:116,497,186...116,524,302
Ensembl chr 3:116,498,022...116,524,366
|
|
G |
Ckap4 |
cytoskeleton-associated protein 4 |
disease_progression |
ISO |
associated with tumor vascularization; mRNA,protein:increased expression:liver tumor (human) |
RGD |
PMID:30901224 |
RGD:152995286 |
NCBI chr 7:19,230,814...19,238,914
Ensembl chr 7:19,230,203...19,238,914
|
|
G |
Cldn1 |
claudin 1 |
severity |
IEP |
protein:increased expression:liver (human) associated with liver cirrhosis;protein:increased expression:liver (human) protein:decreased expression:liver (human) |
RGD |
PMID:24815833 PMID:24696415 PMID:17270214 |
RGD:26884345, RGD:26884352, RGD:26884348 |
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Clec1b |
C-type lectin domain family 1, member B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 4:162,847,978...162,856,291
Ensembl chr 4:162,848,010...162,856,291
|
|
G |
Clec4g |
C-type lectin domain family 4, member G |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr12:1,780,370...1,785,027
Ensembl chr12:1,780,371...1,784,985
|
|
G |
Clec4m |
C-type lectin domain family 4 member M |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr12:1,915,902...1,924,529
Ensembl chr12:1,915,919...1,924,539
|
|
G |
Clptm1l |
CLPTM1-like |
susceptibility disease_progression |
ISO |
DNA:SNPs::rs401681(human) DNA:SNP: :rs401681(human) |
RGD |
PMID:25339005 PMID:29042796 |
RGD:150530496, RGD:150537100 |
NCBI chr 1:29,667,545...29,683,530
Ensembl chr 1:29,667,545...29,683,530
|
|
G |
Cltrn |
collectrin, amino acid transport regulator |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr X:30,361,967...30,395,264
Ensembl chr X:30,361,967...30,395,349
|
|
G |
Cndp1 |
carnosine dipeptidase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr18:77,984,886...78,030,837
Ensembl chr18:77,984,907...78,007,765
|
|
G |
Cnot9 |
CCR4-NOT transcription complex subunit 9 |
|
ISO |
ClinVar Annotator: match by term: Hepatocellular carcinoma |
ClinVar |
PMID:26619011 |
|
NCBI chr 9:76,084,269...76,109,111
Ensembl chr 9:76,084,334...76,109,100
|
|
G |
Cntnap4 |
contactin associated protein family member 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr19:40,568,684...40,861,879
Ensembl chr19:40,568,684...40,854,656
|
|
G |
Col15a1 |
collagen type XV alpha 1 chain |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 5:61,501,963...61,607,591
Ensembl chr 5:61,501,963...61,607,591
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
severity |
IDA |
Protein:increased expression |
RGD |
PMID:15739185 |
RGD:1600906 |
NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593
|
|
G |
Colec10 |
collectin subfamily member 10 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 7:85,744,895...85,806,368
Ensembl chr 7:85,744,895...85,805,675
|
|
G |
Comt |
catechol-O-methyltransferase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15341023 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cops5 |
COP9 signalosome subunit 5 |
severity |
ISO |
CTD Direct Evidence: marker/mechanism protein:increased expression:liver (human) |
CTD RGD |
PMID:20698225 PMID:26606000 |
RGD:11354707 |
NCBI chr 5:9,192,233...9,210,498
Ensembl chr 5:9,192,100...9,210,731
|
|
G |
Cox7b2 |
cytochrome c oxidase subunit 7B2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr14:36,693,120...36,805,323
Ensembl chr14:36,693,105...36,805,523
|
|
G |
Cp |
ceruloplasmin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19229483 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Cpeb3 |
cytoplasmic polyadenylation element binding protein 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 1:234,749,138...234,931,219
Ensembl chr 1:234,751,733...234,931,560
|
|
G |
Cps1 |
carbamoyl-phosphate synthase 1 |
disease_progression |
ISO |
associated with tumor vascularization; mRNA,protein:decreased expression:liver tumor (human) |
RGD |
PMID:30901224 |
RGD:152995286 |
NCBI chr 9:68,614,153...68,737,037
Ensembl chr 9:68,614,153...68,737,033
|
|
G |
Crebbp |
CREB binding protein |
|
ISO |
ClinVar Annotator: match by term: Hepatocellular cancer | ClinVar Annotator: match by term: LIVER CELL CARCINOMA |
ClinVar |
PMID:21390126 PMID:21680795 PMID:21796119 PMID:22832583 PMID:23334668 PMID:23685749 PMID:23778141 PMID:26087898 PMID:26619011 PMID:27257180 PMID:28492532 PMID:28970362 PMID:29551561 PMID:33560380 More...
|
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Crhbp |
corticotropin releasing hormone binding protein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 2:26,692,403...26,704,710
Ensembl chr 2:26,692,403...26,704,710
|
|
G |
Crp |
C-reactive protein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19363144 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
severity exacerbates |
ISO |
DNA:hypomethylation:promoter (human) protein:increased expression:liver (human) protein:increased expression: liver (human) |
RGD |
PMID:32724427 PMID:14969845 PMID:11412385 PMID:32760707 |
RGD:150524282, RGD:150524302, RGD:150524301, RGD:150524286 |
NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415
|
|
G |
Csf2 |
colony stimulating factor 2 |
treatment |
ISO |
|
RGD |
PMID:12731087 |
RGD:10450243 |
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csk |
C-terminal Src kinase |
|
IEP |
protein:decreased expression:liver |
RGD |
PMID:9918913 |
RGD:5134372 |
NCBI chr 8:58,029,748...58,048,742
Ensembl chr 8:58,029,749...58,048,292
|
|
G |
Csmd1 |
CUB and Sushi multiple domains 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr16:72,218,189...73,818,380
Ensembl chr16:72,218,503...73,817,614
|
|
G |
Cspg4 |
chondroitin sulfate proteoglycan 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 8:57,264,962...57,300,010
Ensembl chr 8:57,264,962...57,300,010
|
|
G |
Csrnp1 |
cysteine and serine rich nuclear protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 8:119,704,712...119,717,767
Ensembl chr 8:119,704,713...119,718,183
|
|
G |
Ctla4 |
cytotoxic T-lymphocyte-associated protein 4 |
susceptibility |
ISO |
protein:increased expression:CD4+ and CD8+ T cells: DNA:SNPs: :rs231775,rs231725(human) |
RGD |
PMID:28648905 PMID:23432218 |
RGD:14398741, RGD:14398742 |
NCBI chr 9:62,318,874...62,325,978
Ensembl chr 9:62,319,312...62,324,963
|
|
G |
Ctnnb1 |
catenin beta 1 |
exacerbates severity susceptibility |
ISO |
DNA:mutation:exon 3 ClinVar Annotator: match by term: Hepatocellular cancer | ClinVar Annotator: match by term: Hepatocellular carcinoma | ClinVar Annotator: match by term: LIVER CELL CARCINOMA DNA:missense mutations:exon 3:multiple (human) DNA:Mutations:exon: protein:increased expression:liver: associated with hepatitis B;DNA:SNPs: :rs3864004,rs11564475(human) associated with Hepatitis B, Chronic,DNA:SNP, haplotype: :rs3864004 (human) CTD Direct Evidence: marker/mechanism |
ClinVar CTD OMIM RGD |
PMID:9065402 PMID:9065403 PMID:9294210 PMID:9500465 PMID:9927029 PMID:10027390 PMID:10192393 PMID:10391090 PMID:10398436 PMID:10435629 PMID:10655994 PMID:10666372 PMID:11351304 PMID:11930117 PMID:11950921 PMID:12124804 PMID:15133491 PMID:19234609 PMID:20118494 PMID:21147764 PMID:21903672 PMID:23033978 PMID:23265383 PMID:24614104 PMID:24728327 PMID:24788118 PMID:25157968 PMID:25326635 PMID:25326669 PMID:25741868 PMID:25822088 PMID:26350204 PMID:26502894 PMID:26619011 PMID:26822237 PMID:27738331 PMID:27915094 PMID:27959697 PMID:28284560 PMID:28492532 PMID:28575650 PMID:29682453 PMID:30640974 PMID:10435629 PMID:27276713 PMID:19101982 PMID:19101982 PMID:28328801 PMID:26968103 More...
|
RGD:734850, RGD:150429592, RGD:14402052, RGD:14402052, RGD:14402040, RGD:14402039 |
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsb |
cathepsin B |
|
IDA |
|
RGD |
PMID:15641152 |
RGD:2315605 |
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsd |
cathepsin D |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21472284 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsl |
cathepsin L |
|
IDA |
|
RGD |
PMID:15641152 |
RGD:2315605 |
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Cux1 |
cut-like homeobox 1 |
|
ISO |
mRNA:increased expression:liver (human) |
RGD |
PMID:30561038 |
RGD:152985541 |
NCBI chr12:20,107,062...20,425,868
Ensembl chr12:20,107,311...20,425,866
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
disease_progression treatment |
ISO |
|
RGD |
PMID:28592115 PMID:27245433 PMID:28638480 |
RGD:27095889, RGD:27095899, RGD:27095898 |
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
|
ISO |
mRNA:increased expression:liver (mouse) |
RGD |
PMID:26569409 |
RGD:11344640 |
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19363144 PMID:28284560 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
treatment severity |
ISO |
human cells in mouse model protein:increased expression:liver (human) |
RGD |
PMID:30034941 PMID:33574707 |
RGD:151665331, RGD:151665327 |
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyld |
CYLD lysine 63 deubiquitinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21109933 |
|
NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15341023 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15341023 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp26b1 |
cytochrome P450, family 26, subfamily b, polypeptide 1 |
disease_progression |
ISO |
mRNA:increased expression:liver (human) |
RGD |
PMID:35693827 |
RGD:153344586 |
NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
susceptibility |
ISO |
associated with hepatitis C; DNA:polymorphisms: : |
RGD |
PMID:11021356 |
RGD:124713413 |
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism DNA, mRNA:SNP, Decreased expression:liver: rs2031920 (human) associated with alcohol dependence |
CTD RGD |
PMID:15162526 PMID:29765251 PMID:20364586 |
RGD:14700899, RGD:14700882 |
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp39a1 |
cytochrome P450, family 39, subfamily a, polypeptide 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 9:17,230,455...17,306,775
Ensembl chr 9:17,230,455...17,306,775
|
|
G |
Dab2ip |
DAB2 interacting protein |
severity |
ISO |
mRNA:decreased expression:liver (human) protein:decreased expression:liver (human) |
RGD |
PMID:31176165 PMID:22168621 |
RGD:151665110, RGD:151665148 |
NCBI chr 3:18,915,290...19,086,282
Ensembl chr 3:18,915,290...19,086,280
|
|
G |
Dbh |
dopamine beta-hydroxylase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248
|
|
G |
Dcn |
decorin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
severity |
ISO |
mRNA:increased expression:liver (human) |
RGD |
PMID:33173221 PMID:33173221 |
RGD:151347691, RGD:151347691 |
NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468
|
|
G |
Ddr2 |
discoidin domain receptor tyrosine kinase 2 |
treatment disease_progression |
ISO |
|
RGD |
PMID:33969575 PMID:26362312 |
RGD:150429748, RGD:11086753 |
NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363
|
|
G |
Ddx3x |
DEAD-box helicase 3, X-linked |
exacerbates sexual_dimorphism |
ISO |
associated with hepatitis B; mRNA,protein:decreased expression:liver (human) |
RGD |
PMID:30297359 PMID:16301996 |
RGD:151356499, RGD:151356660 |
NCBI chr X:9,479,532...9,493,169
Ensembl chr X:9,479,532...9,493,168
|
|
G |
Depdc1 |
DEP domain containing 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 2:248,684,508...248,717,951
Ensembl chr 2:248,684,523...248,717,951
|
|
G |
Depdc1b |
DEP domain containing 1B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 2:39,891,163...39,963,779
Ensembl chr 2:39,891,481...39,963,779
|
|
G |
Depdc5 |
DEP domain containing 5, GATOR1 subcomplex subunit |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21725309 |
|
NCBI chr14:77,732,297...77,862,924
Ensembl chr14:77,732,297...77,862,794
|
|
G |
Dhfr |
dihydrofolate reductase |
|
ISO |
ClinVar Annotator: match by term: Hepatocellular cancer |
ClinVar |
PMID:28492532 |
|
NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713
|
|
G |
Dicer1 |
dicer 1 ribonuclease III |
susceptibility |
ISO |
associated with hepatitis B; DNA:SNP: :rs1057035 T>C (human) |
RGD |
PMID:23868705 |
RGD:149735346 |
NCBI chr 6:123,627,529...123,692,278
Ensembl chr 6:123,631,250...123,693,965
|
|
G |
Dipk2b |
divergent protein kinase domain 2B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr X:4,205,486...4,274,939
Ensembl chr X:4,205,490...4,271,574
|
|
G |
Diras3 |
DIRAS family GTPase 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 6:130,524,972...130,526,186
Ensembl chr 6:130,524,742...130,530,825
|
|
G |
Dlgap5 |
DLG associated protein 5 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
|
ISO |
mRNA:increased expression:liver (mouse) |
RGD |
PMID:26569409 |
RGD:11344640 |
NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522
|
|
G |
Dmgdh |
dimethylglycine dehydrogenase |
disease_progression |
ISO |
associated with tumor vascularization; mRNA,protein:decreased expression:liver tumor (human) |
RGD |
PMID:30901224 |
RGD:152995286 |
NCBI chr 2:24,912,600...24,987,533
Ensembl chr 2:24,912,578...24,987,528
|
|
G |
Dnajc6 |
DnaJ heat shock protein family (Hsp40) member C6 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 5:116,120,069...116,283,448
Ensembl chr 5:116,119,676...116,283,448
|
|
G |
Dnase1l3 |
deoxyribonuclease 1-like 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr15:16,922,335...16,948,322
Ensembl chr15:16,922,335...16,948,317
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
|
IEP |
mRNA, protein:increased expression:liver |
RGD |
PMID:11844796 |
RGD:2289670 |
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
|
ISO IEP |
protein:increased expression:liver: mRNA, protein:increased expression:liver |
RGD |
PMID:15885882 PMID:11844796 |
RGD:9588598, RGD:2289670 |
NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
|
ISO IEP |
mRNA:increased expression:liver: mRNA, protein:increased expression:liver |
RGD |
PMID:15885882 PMID:11844796 |
RGD:9588598, RGD:2289670 |
NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18019677 |
|
NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982
|
|
G |
Dsn1 |
DSN1 component of MIS12 kinetochore complex |
disease_progression |
ISO |
|
RGD |
PMID:30136646 |
RGD:27372884 |
NCBI chr 3:145,652,741...145,668,025
Ensembl chr 3:145,652,737...145,665,856
|
|
G |
Dtl |
denticleless E3 ubiquitin protein ligase homolog |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr13:103,115,810...103,155,029
Ensembl chr13:103,117,186...103,154,890
|
|
G |
Dynlrb1 |
dynein light chain roadblock-type 1 |
|
ISO |
|
RGD |
PMID:11750132 |
RGD:13208527 |
NCBI chr 3:143,742,427...143,764,227
Ensembl chr 3:143,742,586...143,764,227
|
|
G |
Dynlrb2 |
dynein light chain roadblock-type 2 |
|
ISO |
|
RGD |
PMID:11750132 |
RGD:13208527 |
NCBI chr19:44,520,134...44,531,384
Ensembl chr19:44,520,134...44,531,387
|
|
G |
E2f1 |
E2F transcription factor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12029619 PMID:15565109 PMID:28284560 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
E2f8 |
E2F transcription factor 8 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
|
|
G |
Eaf2 |
ELL associated factor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20564326 |
|
NCBI chr11:63,960,200...64,004,610
Ensembl chr11:63,960,200...64,004,610
|
|
G |
Ecm1 |
extracellular matrix protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 2:183,287,491...183,292,729
Ensembl chr 2:183,287,322...183,292,671
|
|
G |
Ect2 |
epithelial cell transforming 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 2:109,975,813...110,037,911
Ensembl chr 2:109,975,813...110,037,911
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
exacerbates |
ISO |
protein:increased expression, increased phosphorylation:liver (human) |
RGD |
PMID:28060762 |
RGD:153298915 |
NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
|
|
G |
Efemp1 |
EGF containing fibulin extracellular matrix protein 1 |
disease_progression |
ISO |
protein:decreased expression:liver: |
RGD |
PMID:23936443 |
RGD:10401793 |
NCBI chr14:102,610,813...102,690,027
Ensembl chr14:102,610,908...102,690,018
|
|
G |
Eftud2 |
elongation factor Tu GTP binding domain containing 2 |
severity ameliorates |
ISO |
|
RGD |
PMID:34282556 PMID:34282556 |
RGD:155791664, RGD:155791664 |
NCBI chr10:87,804,893...87,852,181
Ensembl chr10:87,804,892...87,846,079
|
|
G |
Egf |
epidermal growth factor |
susceptibility |
ISO |
CTD Direct Evidence: marker/mechanism associated with hepatitis B;DNA:SNP:exon: (rs11569017) (human) associated with liver cirrhosis;DNA:SNP:5'UTR: (rs4444903) (human) |
CTD RGD |
PMID:9029167 PMID:23790025 PMID:18167406 |
RGD:14695014, RGD:14695013 |
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
disease_progression |
ISO |
CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:9029167 PMID:11355950 |
RGD:126781769 |
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Ehd3 |
EH-domain containing 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 6:21,640,861...21,665,601
Ensembl chr 6:21,639,290...21,665,236
|
|
G |
Eif3h |
eukaryotic translation initiation factor 3, subunit H |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:14578863 |
|
NCBI chr 7:83,091,037...83,174,451
Ensembl chr 7:83,091,039...83,174,451
|
|
G |
Enah |
ENAH, actin regulator |
disease_progression |
ISO |
mRNA:increased expression:liver (human) |
RGD |
PMID:35030977 |
RGD:155791678 |
NCBI chr13:93,617,747...93,738,119
Ensembl chr13:93,626,944...93,740,955
|
|
G |
Eng |
endoglin |
|
IEP |
protein:increased expression:liver (rat) |
RGD |
PMID:20368095 |
RGD:7257538 |
NCBI chr 3:15,934,566...15,972,618
Ensembl chr 3:15,934,518...15,973,230
|
|
G |
Eno1 |
enolase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21472284 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Ep300 |
E1A binding protein p300 |
|
IEP |
protein:increased expression:liver (rat) |
RGD |
PMID:17083329 |
RGD:2312274 |
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26735578 |
|
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Epcam |
epithelial cell adhesion molecule |
severity |
ISO |
protein:increased expression:liver |
RGD |
PMID:24616575 |
RGD:14695007 |
NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127
|
|
G |
Ephb1 |
Eph receptor B1 |
|
ISO |
protein:increased phosphorylation:liver (mouse) |
RGD |
PMID:28100771 |
RGD:127285675 |
NCBI chr 8:102,507,549...102,944,839
Ensembl chr 8:102,507,549...102,944,839
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:7892276 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Epo |
erythropoietin |
disease_progression |
ISO |
mRNA:increased expression:liver (human) |
RGD |
PMID:35693827 |
RGD:153344586 |
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Eps8l3 |
EPS8 like 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 2:195,514,692...195,528,085
Ensembl chr 2:195,514,692...195,528,085
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
disease_progression |
ISO |
|
RGD |
PMID:11355950 |
RGD:126781769 |
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
|
ISO |
DNA:insertion/deletion:3'UTR:rs6147150 (human) |
RGD |
PMID:22294845 |
RGD:126781763 |
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
|
ISO |
mRNA, protein:increased expression:liver (human) |
RGD |
PMID:15922480 |
RGD:155598683 |
NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
|
|
G |
Ercc2 |
ERCC excision repair 2, TFIIH core complex helicase subunit |
susceptibility disease_progression |
ISO |
DNA:SNPs:exon 23: p.K751Q (human) DNA:SNP:cd: 312A>G (human) DNA:SNPs:exon 23: p.K751Q (rs13181) (human) DNA:SNPs:exon 23: p.K751Q (human) |
RGD |
PMID:19919686 PMID:28927037 PMID:28598207 PMID:25531380 |
RGD:25671459, RGD:150530503, RGD:25671461, RGD:25671460 |
NCBI chr 1:79,033,342...79,047,102
Ensembl chr 1:79,033,326...79,047,102
|
|
G |
Ereg |
epiregulin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:35776891 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
|
ISO |
DNA:hypomethylation: CpG islands: |
RGD |
PMID:20165882 |
RGD:14694974 |
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Erp29 |
endoplasmic reticulum protein 29 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21472284 |
|
NCBI chr12:35,089,698...35,095,952
Ensembl chr12:35,089,707...35,096,376
|
|
G |
Esm1 |
endothelial cell-specific molecule 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 2:44,876,067...44,884,805
Ensembl chr 2:44,876,067...44,884,804
|
|
G |
Esr1 |
estrogen receptor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19363144 PMID:28284560 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Etfa |
electron transfer flavoprotein subunit alpha |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21472284 |
|
NCBI chr 8:55,835,115...55,891,890
Ensembl chr 8:55,835,134...55,891,969
|
|
G |
Exo1 |
exonuclease 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
susceptibility |
ISO |
mRNA:increased expression:liver (human) CTD Direct Evidence: marker/mechanism DNA:SNPs: :multiple |
CTD RGD |
PMID:28284560 PMID:34545456 PMID:24211739 PMID:25226601 PMID:24040354 PMID:26517514 More...
|
RGD:10755339, RGD:126779608, RGD:126779595, RGD:11537550 |
NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362
|
|
G |
F2 |
coagulation factor II, thrombin |
severity |
ISO |
CTD Direct Evidence: marker/mechanism associated with liver cirrhosis;protein:altered expression, altered processing:liver (human) |
CTD RGD |
PMID:2821104 PMID:7620113 |
RGD:14975114 |
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21472284 |
|
NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773
|
|
G |
Fam180a |
family with sequence similarity 180, member A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 4:63,992,867...64,008,047
Ensembl chr 4:63,992,867...64,008,047
|
|
G |
Fam83d |
family with sequence similarity 83, member D |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 3:147,421,941...147,441,211
Ensembl chr 3:147,421,908...147,441,192
|
|
G |
Fancd2 |
FA complementation group D2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412
|
|
G |
Fanci |
FA complementation group I |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 1:133,327,264...133,383,661
Ensembl chr 1:133,327,297...133,383,640
|
|
G |
Fas |
Fas cell surface death receptor |
treatment |
IEP ISO |
protein:increased expression:liver: |
RGD |
PMID:29634416 PMID:30737368 PMID:11274632 |
RGD:13792608, RGD:14700700, RGD:14700677 |
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
|
ISO |
protein:increased expression:liver: |
RGD |
PMID:11274632 |
RGD:14700677 |
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fasn |
fatty acid synthase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:14563831 PMID:15543204 PMID:21147110 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fat1 |
FAT atypical cadherin 1 |
disease_progression |
ISO |
mRNA,protein:increased expression:liver (human) |
RGD |
PMID:24590895 |
RGD:151347630 |
NCBI chr16:47,177,253...47,296,261
Ensembl chr16:47,177,248...47,296,107
|
|
G |
Fbp1 |
fructose-bisphosphatase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22039417 |
|
NCBI chr17:2,207,271...2,230,076
Ensembl chr17:2,208,031...2,230,071
|
|
G |
Fbxl18 |
F-box and leucine-rich repeat protein 18 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr12:11,674,538...11,701,317
Ensembl chr12:11,676,115...11,699,181
|
|
G |
Fbxo11 |
F-box protein 11 |
exacerbates ameliorates |
ISO |
mRNA:increased expression:liver (human) |
RGD |
PMID:32657545 PMID:29518611 |
RGD:152025263, RGD:152025259 |
NCBI chr 6:6,486,761...6,562,664
Ensembl chr 6:6,486,015...6,562,662
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21147110 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fes |
FES proto-oncogene, tyrosine kinase |
exacerbates |
ISO |
DNA:hypermethylation:promoter (human) |
RGD |
PMID:31038805 |
RGD:153323297 |
NCBI chr 1:134,337,698...134,346,934
Ensembl chr 1:134,337,698...134,346,934
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25822088 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
Fgf3 |
fibroblast growth factor 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25822088 |
|
NCBI chr 1:200,001,162...200,005,539
Ensembl chr 1:200,001,261...200,005,187
|
|
G |
Fgf4 |
fibroblast growth factor 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25822088 |
|
NCBI chr 1:200,023,937...200,027,793
Ensembl chr 1:200,024,056...200,025,466
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
treatment |
ISO |
CTD Direct Evidence: marker/mechanism ClinVar Annotator: match by term: Hepatocellular carcinoma |
CTD ClinVar RGD |
PMID:25705862 PMID:26619011 PMID:26942290 PMID:33448156 PMID:36029209 PMID:16452204 PMID:20155451 PMID:21573021 More...
|
RGD:25330358, RGD:25440478, RGD:25440476 |
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
severity |
ISO |
associated with hepatitis B;DNA:SNPs: promoter, intron:rs308379, rs1219648 (human) |
RGD |
PMID:30952770 |
RGD:38501096 |
NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
|
|
G |
Fgfr4 |
fibroblast growth factor receptor 4 |
treatment |
ISO |
|
RGD |
PMID:32677805 |
RGD:150520166 |
NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242
|
|
G |
Fh |
fumarate hydratase |
|
ISO |
ClinVar Annotator: match by term: Hepatocellular carcinoma |
ClinVar |
PMID:10896297 PMID:15221078 PMID:16876016 PMID:17182618 PMID:18313410 PMID:19151755 PMID:20301679 PMID:21445611 PMID:25637381 PMID:25741868 PMID:28492532 PMID:28747166 More...
|
|
NCBI chr13:87,524,331...87,550,215
Ensembl chr13:87,524,337...87,550,266
|
|
G |
Fhit |
fragile histidine triad diadenosine triphosphatase |
|
IDA |
|
RGD |
PMID:12112319 |
RGD:632723 |
NCBI chr15:13,935,029...15,442,620
Ensembl chr15:13,934,995...15,442,340
|
|
G |
Flt3 |
Fms related receptor tyrosine kinase 3 |
ameliorates |
ISO |
human cells in mouse model |
RGD |
PMID:27511526 |
RGD:149735514 |
NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474
|
|
G |
Flvcr1 |
FLVCR choline and heme transporter 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr13:102,586,263...102,608,647
Ensembl chr13:102,586,257...102,608,661
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:9029167 PMID:28284560 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
|
ISO |
mRNA:increased expression:liver (human) |
RGD |
PMID:30086463 PMID:32048611 |
RGD:153344517, RGD:153344521 |
NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034
|
|
G |
Foxa1 |
forkhead box A1 |
susceptibility sexual_dimorphism disease_progression |
ISO |
DNA:VNTR, SNPs, haplotypes:multiple: protein:decreased expression:liver |
RGD |
PMID:29208003 PMID:31400761 PMID:25965836 |
RGD:151665820, RGD:151665752, RGD:11054501 |
NCBI chr 6:75,099,907...75,136,534
Ensembl chr 6:75,103,503...75,136,188
|
|
G |
Foxm1 |
forkhead box M1 |
|
ISO ISS |
CTD Direct Evidence: marker/mechanism OMIM:114550 |
CTD MouseDO |
PMID:15082532 PMID:17173139 PMID:28284560 |
|
NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684
|
|
G |
Foxo1 |
forkhead box O1 |
|
ISO |
mRNA:decreased expression:liver |
RGD |
PMID:28972178 |
RGD:14401599 |
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Foxp1 |
forkhead box P1 |
treatment |
IEP |
|
RGD |
PMID:25156538 |
RGD:9587823 |
NCBI chr 4:131,559,599...132,155,092
Ensembl chr 4:131,564,756...132,112,258
|
|
G |
Foxp3 |
forkhead box P3 |
|
ISO |
protein:increased expression:liver |
RGD |
PMID:21086571 |
RGD:38548919 |
NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838
|
|
G |
Fst |
follistatin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12203361 PMID:19363144 |
|
NCBI chr 2:46,123,260...46,130,584
Ensembl chr 2:46,123,439...46,130,571
|
|
G |
Fth1 |
ferritin heavy chain 1 |
|
IEP |
mRNA:increased expression:liver (rat) |
RGD |
PMID:9054589 |
RGD:632698 |
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Fubp1 |
far upstream element binding protein 1 |
exacerbates ameliorates |
ISO |
mRNA:increased expression:liver (human) associated with Chronic Hepatitis C;mRNA:increased expression:liver (human) human cell line in a mouse model |
RGD |
PMID:31587040 PMID:25995247 PMID:19637194 |
RGD:151361188, RGD:151361196, RGD:151361194 |
NCBI chr 2:241,159,481...241,186,591
Ensembl chr 2:241,159,512...241,186,602
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
treatment |
ISO |
associated with Glycogen Storage Disease IA, human gene in a mouse model |
RGD |
PMID:28096054 |
RGD:14695537 |
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
disease_progression |
IEP ISO |
mRNA:increased expression:liver (human) |
RGD |
PMID:25473368 PMID:35693827 |
RGD:10449118, RGD:153344586 |
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gabrd |
gamma-aminobutyric acid type A receptor subunit delta |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 5:165,958,508...165,970,407
Ensembl chr 5:165,958,484...165,970,411
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16767786 PMID:21472284 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gba3 |
glucosylceramidase beta 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr14:60,574,974...60,721,411
Ensembl chr14:60,574,976...60,721,653
|
|
G |
Gc |
GC, vitamin D binding protein |
susceptibility |
IEP ISO |
protein:increased expression:liver associated with Hepatitis B, Chronic;DNA:SNP: :rs7041(human) |
RGD |
PMID:21683810 PMID:25541958 |
RGD:5509919, RGD:14402025 |
NCBI chr14:18,632,146...18,667,563
Ensembl chr14:18,632,135...18,667,567
|
|
G |
Gdf15 |
growth differentiation factor 15 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20512989 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gdf2 |
growth differentiation factor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23936038 PMID:28284560 |
|
NCBI chr16:9,255,430...9,261,429
Ensembl chr16:9,255,430...9,261,429
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
disease_progression |
ISO |
RNA,protein:increased expression, activity:liver: HBV associated |
RGD |
PMID:11940314 PMID:10572675 PMID:27793641 |
RGD:14701040, RGD:14701048, RGD:14701041 |
NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
|
|
G |
Ghr |
growth hormone receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735
|
|
G |
Gins1 |
GINS complex subunit 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 3:139,724,513...139,745,930
Ensembl chr 3:139,724,490...139,745,936
|
|
G |
Gjb1 |
gap junction protein, beta 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17978847 |
|
NCBI chr X:66,501,848...66,509,783
Ensembl chr X:66,501,820...66,509,925
|
|
G |
Gjb2 |
gap junction protein, beta 2 |
|
IDA |
DNA, mRNA:promoter hypermethylation, decreased expression:liver |
RGD |
PMID:17295234 |
RGD:2289638 |
NCBI chr15:31,260,390...31,278,222
Ensembl chr15:31,260,357...31,278,177
|
|
G |
Gli1 |
GLI family zinc finger 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26189965 |
|
NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251
|
|
G |
Glul |
glutamate-ammonia ligase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19363144 |
|
NCBI chr13:65,969,053...66,035,121
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gmnn |
geminin, DNA replication inhibitor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr17:40,301,771...40,310,054
Ensembl chr17:40,301,808...40,310,054
|
|
G |
Gmps |
guanine monophosphate synthase |
|
IEP |
protein:increased activity:hepatoma (rat) |
RGD |
PMID:6861338 |
RGD:5135537 |
NCBI chr 2:148,441,369...148,491,908
Ensembl chr 2:148,435,643...148,485,875
|
|
G |
Gnao1 |
G protein subunit alpha o1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr19:11,034,874...11,192,531
Ensembl chr19:11,035,956...11,192,493
|
|
G |
Gnas |
GNAS complex locus |
|
ISO |
ClinVar Annotator: match by term: Hepatocellular cancer | ClinVar Annotator: match by term: Hepatocellular carcinoma |
ClinVar |
PMID:1517386 PMID:1594625 PMID:1944469 PMID:2549426 PMID:3720010 PMID:7739708 PMID:8766942 PMID:9626141 PMID:11093740 PMID:12727968 PMID:12970318 PMID:15126527 PMID:15952988 PMID:16507630 PMID:16543670 PMID:17873334 PMID:20197676 PMID:21835143 PMID:23403822 PMID:23536913 PMID:23843956 PMID:24855271 PMID:25157968 PMID:25719192 PMID:25741868 PMID:26619011 PMID:27398169 PMID:27506760 PMID:28492532 PMID:30702195 More...
|
|
NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Gnaz |
G protein subunit alpha z |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr20:13,643,473...13,694,240
Ensembl chr20:13,644,640...13,669,907
|
|
G |
Gnmt |
glycine N-methyltransferase |
|
ISO ISS |
CTD Direct Evidence: marker/mechanism OMIM:114550 |
CTD MouseDO |
PMID:19146867 PMID:31086990 |
|
NCBI chr 9:14,254,675...14,258,028
Ensembl chr 9:14,254,675...14,258,434
|
|
G |
Golm1 |
golgi membrane protein 1 |
severity |
ISO |
protein:increased expression:serum mRNA, protein:increased expression:liver |
RGD |
PMID:21140449 PMID:21443671 |
RGD:401827118, RGD:401827119 |
NCBI chr17:4,995,925...5,044,329
Ensembl chr17:4,996,104...5,034,057
|
|
G |
Gpc1 |
glypican 1 |
disease_progression |
ISO |
mRNA:increased expression:liver (human) |
RGD |
PMID:35693827 |
RGD:153344586 |
NCBI chr 9:93,396,234...93,424,047
Ensembl chr 9:93,396,234...93,424,047
|
|
G |
Gpc3 |
glypican 3 |
exacerbates disease_progression severity treatment |
ISO IMP |
CTD Direct Evidence: marker/mechanism protein:increased expression:liver (human) protein:increased expression:blood serum (human) mRNA,protein:increased expression:peripheral blood mononuclear cell,blood serum, liver (human) mRNA:increased expression:Peripheral Blood (human) protein:increased expression:serum |
CTD RGD |
PMID:16698587 PMID:27286460 PMID:28284560 PMID:22883669 PMID:28801286 PMID:23558072 PMID:21438004 PMID:25449037 PMID:25449037 PMID:19496787 More...
|
RGD:243065134, RGD:243065139, RGD:243065135, RGD:243065131, RGD:243065125, RGD:14695020, RGD:14695020, RGD:14695019 |
NCBI chr X:131,868,986...132,236,824
Ensembl chr X:131,868,990...132,236,798
|
|
G |
Gpm6a |
glycoprotein m6a |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr16:36,641,282...36,973,377
Ensembl chr16:36,641,284...36,973,475
|
|
G |
Gpr158 |
G protein-coupled receptor 158 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr17:83,777,625...84,244,428
Ensembl chr17:83,834,569...84,244,428
|
|
G |
Gpr182 |
G protein-coupled receptor 182 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 7:63,585,997...63,589,088
Ensembl chr 7:63,578,750...63,589,210
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
severity no_association susceptibility |
ISO |
associated with hepatitis C;DNA:missense mutation:CDS:p.P198L (rs1050450) (human) DNA:missense mutation:CDS:p.P198L (human) associated with alcoholic liver cirrhosis;DNA:missense mutation:CDS:p.P198L (human) |
RGD |
PMID:26990426 PMID:25894370 PMID:19929244 PMID:16510607 |
RGD:11533013, RGD:152998906, RGD:152995483, RGD:151708729 |
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
severity disease_progression |
ISO |
mRNA,protein:decreased expression:liver, blood plasma (human) DNA:hypermethylation |
RGD |
PMID:25333265 PMID:27570561 PMID:25445749 |
RGD:151665355, RGD:401827855, RGD:151665509 |
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Grb7 |
growth factor receptor bound protein 7 |
exacerbates |
ISO |
protein:increased expression:liver (human) |
RGD |
PMID:17634422 |
RGD:151347655 |
NCBI chr10:83,443,387...83,453,057
Ensembl chr10:83,444,004...83,453,052
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
susceptibility no_association |
ISO |
DNA:deletion:cds (human) CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:7892276 PMID:11859714 PMID:20672314 PMID:20683151 |
RGD:7488953, RGD:14700979, RGD:14700951 |
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism DNA:increased methylation:promoter |
CTD RGD |
PMID:9029167 PMID:22536438 |
RGD:14401712 |
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
susceptibility no_association |
ISO |
DNA:deletion |
RGD |
PMID:23053942 PMID:20672314 PMID:20683151 |
RGD:14401714, RGD:14700979, RGD:14700951 |
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Gtse1 |
G-2 and S-phase expressed 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 7:116,949,997...116,966,826
Ensembl chr 7:116,950,053...116,966,806
|
|
G |
Gys2 |
glycogen synthase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 4:175,365,054...175,406,228
Ensembl chr 4:175,365,054...175,406,228
|
|
G |
H19 |
H19 imprinted maternally expressed transcript |
|
IEP |
mRNA:increased expression:liver |
RGD |
PMID:17393425 |
RGD:2306187 |
NCBI chr 1:197,730,698...197,733,374
Ensembl chr 1:197,730,698...197,733,134
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
|
ISO IDA IEP |
CTD Direct Evidence: marker/mechanism DNA:hypermethylation,hypomethylation:promoter mRNA:decreased expression:liver (human) |
CTD RGD |
PMID:28284560 PMID:29235098 PMID:29235098 |
RGD:15042879, RGD:15042879 |
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Hao2 |
hydroxyacid oxidase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 2:186,200,137...186,232,997
Ensembl chr 2:186,200,504...186,224,425
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
disease_progression |
ISO |
mRNA:increased expression:liver (human) |
RGD |
PMID:35693827 |
RGD:153344586 |
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Havcr2 |
hepatitis A virus cellular receptor 2 |
disease_progression |
ISO |
associated with hepatitis B;DNA:SNP: : ���1516 G>T (human) |
RGD |
PMID:27034168 |
RGD:40818257 |
NCBI chr10:30,882,484...30,914,018
Ensembl chr10:30,882,606...30,909,137
|
|
G |
Hdac2 |
histone deacetylase 2 |
disease_progression |
ISO |
mRNA:increased expression:liver: |
RGD |
PMID:24448241 |
RGD:9590206 |
NCBI chr20:40,548,244...40,571,609
Ensembl chr20:40,548,250...40,571,609
|
|
G |
Hdac4 |
histone deacetylase 4 |
|
ISO |
mRNA:increased expression:liver: |
RGD |
PMID:21837748 |
RGD:9681451 |
NCBI chr 9:92,503,467...92,750,164
Ensembl chr 9:92,507,611...92,750,164
|
|
G |
Hfe |
homeostatic iron regulator |
disease_progression |
ISO |
associated with Liver Cirrhosis;DNA:missense mutation:cds:p.C282Y (human) |
RGD |
PMID:20019189 PMID:29642405 |
RGD:2317357, RGD:14746967 |
NCBI chr17:41,413,451...41,421,502
Ensembl chr17:41,413,451...41,421,502
|
|
G |
Hgf |
hepatocyte growth factor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:9932610 PMID:11896611 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hgfac |
HGF activator |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19363144 |
|
NCBI chr14:75,707,588...75,714,182
Ensembl chr14:75,707,591...75,714,278
|
|
G |
Hhip |
Hedgehog-interacting protein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18559595 |
|
NCBI chr19:27,863,684...27,952,528
Ensembl chr19:27,863,213...27,952,528
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
treatment disease_progression |
IMP ISO |
protein:increased expression:liver (human) |
RGD |
PMID:19335982 PMID:31321740 PMID:26078356 |
RGD:9068886, RGD:155882550, RGD:11526468 |
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hilpda |
hypoxia inducible lipid droplet-associated |
disease_progression |
ISO |
mRNA, protein:increased expression:liver (human) mRNA:increased expression:liver (human) human cells in mouse model |
RGD |
PMID:31142329 PMID:35693827 PMID:30205391 PMID:31142329 |
RGD:153344574, RGD:153344586, RGD:153344577, RGD:153344574 |
NCBI chr 4:57,871,088...57,874,048
Ensembl chr 4:57,871,110...57,874,557
|
|
G |
Hjurp |
Holliday junction recognition protein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 9:88,853,379...88,867,730
Ensembl chr 9:88,853,386...88,867,728
|
|
G |
Hmgb2 |
high mobility group box 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20851854 |
|
NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:9207284 PMID:21147110 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
disease_progression |
ISO |
|
RGD |
PMID:28867541 |
RGD:14975299 |
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Hmmr |
hyaluronan-mediated motility receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060
|
|
G |
Hnf1a |
HNF1 homeobox A |
treatment |
IMP |
human cell line in mouse model |
RGD |
PMID:29466992 |
RGD:14700664 |
NCBI chr12:41,638,536...41,672,806
Ensembl chr12:41,645,587...41,672,104
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
|
IEP ISO |
protein:decreased expression:liver: |
RGD |
PMID:20876809 PMID:20876809 |
RGD:12904747, RGD:12904747 |
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Hnrnpa1 |
heterogeneous nuclear ribonucleoprotein A1 |
|
ISO |
protein:increased expression:liver (human) |
RGD |
PMID:23633480 |
RGD:9685423 |
NCBI chr 7:134,375,318...134,381,610
Ensembl chr 7:134,375,150...134,381,609
|
|
G |
Hnrnpa2b1 |
heterogeneous nuclear ribonucleoprotein A2/B1 |
|
ISO IEP |
protein:increased expression:liver (human) mRNA:increased expression:liver (rat) |
RGD |
PMID:20604928 PMID:23633480 |
RGD:9685422, RGD:9685423 |
NCBI chr 4:80,534,659...80,545,297
Ensembl chr 4:80,534,651...80,545,249
|
|
G |
Hnrnpab |
heterogeneous nuclear ribonucleoprotein A/B |
severity |
ISO |
mRNA:increased expression:liver (human) |
RGD |
PMID:24638979 |
RGD:10059322 |
NCBI chr10:35,857,040...35,862,935
Ensembl chr10:35,857,041...35,863,344
|
|
G |
Hnrnpd |
heterogeneous nuclear ribonucleoprotein D |
|
ISO IEP |
protein:increased expression:liver (human) protein:increased expression:liver (rat) |
RGD |
PMID:20102719 PMID:22318685 |
RGD:10042969, RGD:10042977 |
NCBI chr14:9,615,375...9,638,975
Ensembl chr14:9,615,479...9,633,786
|
|
G |
Hnrnph1 |
heterogeneous nuclear ribonucleoprotein H1 |
|
ISO |
protein:increased expression:liver (human) |
RGD |
PMID:23633480 |
RGD:9685423 |
NCBI chr10:34,692,868...34,702,849
Ensembl chr10:34,693,555...34,702,846
|
|
G |
Hnrnpl |
heterogeneous nuclear ribonucleoprotein L |
|
ISO |
associated with Hepatitis B |
RGD |
PMID:24125732 |
RGD:9999429 |
NCBI chr 1:84,098,558...84,111,568
Ensembl chr 1:84,100,879...84,111,553
|
|
G |
Hoxa10 |
homeobox A10 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 4:81,331,591...81,340,878
Ensembl chr 4:81,331,591...81,340,919
|
|
G |
Hoxa13 |
homeo box A13 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 4:81,358,956...81,361,091
Ensembl chr 4:81,358,956...81,361,091
|
|
G |
Hoxd9 |
homeo box D9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 3:59,600,575...59,602,755
Ensembl chr 3:59,600,575...59,602,754
|
|
G |
Hp |
haptoglobin |
|
ISO |
protein:increased expression:saliva protein:decreased expression:liver (human) |
RGD |
PMID:31041878 PMID:24259486 |
RGD:27095881, RGD:152995276 |
NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523
|
|
G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
|
IEP |
protein:increased activity:hepatoma (rat) |
RGD |
PMID:6327016 |
RGD:5135035 |
NCBI chr X:132,736,175...132,768,149
Ensembl chr X:132,736,096...132,768,154
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
treatment |
ISO |
CTD Direct Evidence: marker/mechanism ClinVar Annotator: match by term: Hepatocellular cancer | ClinVar Annotator: match by term: Hepatocellular carcinoma mRNA:increased expression:liver (mouse) human plasmid in a mouse model human cells in a mouse model protein:increased expression:liver (human) |
CTD ClinVar RGD |
PMID:8200073 PMID:9311599 PMID:11150980 PMID:12835555 PMID:16155195 PMID:16170316 PMID:16329078 PMID:16372351 PMID:16443854 PMID:16835863 PMID:16881968 PMID:16969868 PMID:17054105 PMID:17211612 PMID:17384584 PMID:17412879 PMID:17601930 PMID:17979197 PMID:18039947 PMID:18042262 PMID:18247425 PMID:18978862 PMID:19206176 PMID:19213030 PMID:19255327 PMID:19371735 PMID:19382114 PMID:19669404 PMID:19773371 PMID:20118494 PMID:20660566 PMID:20859122 PMID:20937837 PMID:20979192 PMID:21438134 PMID:21495179 PMID:21686750 PMID:21834037 PMID:21850009 PMID:22087699 PMID:22256804 PMID:22317973 PMID:22420426 PMID:22495892 PMID:22499344 PMID:22683711 PMID:22726224 PMID:22926243 PMID:23093928 PMID:23096712 PMID:23406027 PMID:23429430 PMID:23751039 PMID:23884457 PMID:24006476 PMID:24033266 PMID:24129065 PMID:24169525 PMID:24224811 PMID:24390138 PMID:24803665 PMID:25157968 PMID:25326635 PMID:25741868 PMID:25815234 PMID:25914166 PMID:26467025 PMID:26619011 PMID:26778095 PMID:27195699 PMID:27283355 PMID:27444071 PMID:27517622 PMID:27589201 PMID:28027064 PMID:28139825 PMID:28284560 PMID:28492532 PMID:29493581 PMID:30055033 PMID:30138938 PMID:30191474 PMID:31394527 PMID:31560489 PMID:31564432 PMID:31775759 PMID:32371413 PMID:32732226 PMID:33027564 PMID:33372952 PMID:34008892 PMID:34958143 PMID:168335863 PMID:2219132 PMID:23555816 PMID:10791191 PMID:15806265 More...
|
RGD:14694810, RGD:14694809, RGD:14688055, RGD:14688054 |
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19363144 |
|
NCBI chr 2:186,095,897...186,105,354
Ensembl chr 2:186,095,897...186,101,852
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21472284 PMID:29698666 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21472284 |
|
NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21472284 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Htatip2 |
HIV-1 Tat interactive protein 2 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:16799960 |
|
NCBI chr 1:99,473,411...99,488,632
Ensembl chr 1:99,469,245...99,488,629
|
|
G |
Htra1 |
HtrA serine peptidase 1 |
exacerbates disease_progression |
ISO |
protein:decreased expression:liver (human) mRNA:decreased expression:liver (human) |
RGD |
PMID:20943460 PMID:26403966 |
RGD:152985524, RGD:152985529 |
NCBI chr 1:185,497,815...185,547,380
Ensembl chr 1:185,497,735...185,547,379
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
severity |
ISO |
protein:increased expression:serum |
RGD |
PMID:26109813 |
RGD:11056752 |
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Idh1 |
isocitrate dehydrogenase (NADP(+)) 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism ClinVar Annotator: match by term: Hepatocellular cancer |
CTD ClinVar |
PMID:18772396 PMID:19657110 PMID:19798509 PMID:19818334 PMID:20946881 PMID:21352804 PMID:21446021 PMID:21472284 PMID:22160010 PMID:22397365 PMID:22417203 PMID:22898539 PMID:23558169 PMID:24606448 PMID:25043048 PMID:25157968 PMID:25741868 PMID:26619011 PMID:27993330 PMID:30231226 PMID:36201590 More...
|
|
NCBI chr 9:66,534,146...66,563,703
Ensembl chr 9:66,534,146...66,563,708
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
disease_progression |
ISO |
ClinVar Annotator: match by term: Hepatocellular cancer |
ClinVar RGD |
PMID:20946881 PMID:21250968 PMID:21596855 PMID:21997850 PMID:22160010 PMID:22397365 PMID:22417203 PMID:22616558 PMID:22898539 PMID:23949315 PMID:24606448 PMID:25157968 PMID:26619011 PMID:24716838 More...
|
RGD:14985249 |
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Ier2 |
immediate early response 2 |
|
ISO |
mRNA, protein:decreased expression:liver (human) |
RGD |
PMID:32009420 |
RGD:153323326 |
NCBI chr19:23,494,551...23,496,075
Ensembl chr19:23,494,184...23,499,211
|
|
G |
Ifna1 |
interferon, alpha 1 |
susceptibility |
ISO |
CTD Direct Evidence: therapeutic associated with hepatitis B; DNA:SNP:: ( rs1831583) (human) |
CTD RGD |
PMID:17088986 PMID:17971768 PMID:18665156 PMID:29080269 |
RGD:21406429 |
NCBI chr 5:103,097,356...103,097,925
Ensembl chr 5:103,097,356...103,097,925
|
|
G |
Ifng |
interferon gamma |
|
ISO |
mRNA:increased expression:liver (mouse) |
RGD |
PMID:26569409 |
RGD:11344640 |
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ifnl1 |
interferon, lambda 1 |
ameliorates |
ISO |
human protein and cells in mouse model |
RGD |
PMID:24769671 |
RGD:126848750 |
NCBI chr 1:83,798,651...83,800,297
Ensembl chr 1:83,798,703...83,800,235
|
|
G |
Igbp1 |
immunoglobulin binding protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21339737 |
|
NCBI chr X:65,582,832...65,605,078
Ensembl chr X:65,582,821...65,606,049
|
|
G |
Igf1 |
insulin-like growth factor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
susceptibility |
ISO |
CTD Direct Evidence: marker/mechanism DNA:SNPs, haplotype: : |
CTD RGD |
PMID:17441810 PMID:23958494 PMID:24758241 |
RGD:14985227 |
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Igf2 |
insulin-like growth factor 2 |
susceptibility |
IEP ISO |
associated with hepatitis B;DNA:SNPs:intron, 3'utr:+2482A>C, +820A>G (human) CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:12532445 PMID:16092956 PMID:17554210 PMID:16750516 |
RGD:2311523, RGD:14401723 |
NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018
|
|
G |
Igf2bp1 |
insulin-like growth factor 2 mRNA binding protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr10:80,908,300...80,951,097
Ensembl chr10:80,908,076...80,951,129
|
|
G |
Igf2bp3 |
insulin-like growth factor 2 mRNA binding protein 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 4:78,060,494...78,195,007
Ensembl chr 4:78,060,494...78,194,865
|
|
G |
Igf2r |
insulin-like growth factor 2 receptor |
treatment no_association disease_progression |
ISO |
DNA:mutation:G1449V (human) ClinVar Annotator: match by term: Hepatocellular carcinoma associated with hepatitis B virus; mRNA:decreased expression:liver: DNA:loss of heterozygosity,mutations:liver: DNA:loss of heterozygosity:liver protein:increased expression:serum: CTD Direct Evidence: marker/mechanism |
ClinVar CTD OMIM RGD |
PMID:9722161 PMID:15057872 PMID:25741868 PMID:7493029 PMID:12736721 PMID:11981765 PMID:30720132 PMID:10347113 PMID:18322954 PMID:29940770 More...
|
RGD:1624323, RGD:14985225, RGD:14985222, RGD:14985221, RGD:14985220, RGD:14985219, RGD:14985218 |
NCBI chr 1:47,979,109...48,067,501
Ensembl chr 1:47,979,109...48,067,501
|
|
G |
Igfals |
insulin-like growth factor binding protein, acid labile subunit |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr10:13,897,468...13,903,920
Ensembl chr10:13,898,395...13,902,677
|
|
G |
Ikbkg |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
treatment |
ISO |
protein:decreased expression:liver (human) |
RGD |
PMID:29551768 PMID:22922425 PMID:24971483 PMID:17292824 PMID:25173965 PMID:22176836 More...
|
RGD:153297807, RGD:153305947, RGD:11079569, RGD:153305945, RGD:153305943, RGD:153297813 |
NCBI chr X:152,216,485...152,241,476
Ensembl chr X:152,216,596...152,239,499
|
|
G |
Ikzf1 |
IKAROS family zinc finger 1 |
ameliorates |
ISO |
protein:increased expression:liver (human) |
RGD |
PMID:25301737 |
RGD:150540326 |
NCBI chr14:86,255,065...86,340,839
Ensembl chr14:86,255,065...86,342,416
|
|
G |
Il10 |
interleukin 10 |
treatment |
IDA ISO |
|
RGD |
PMID:23822114 PMID:26890368 |
RGD:7365006, RGD:14975171 |
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12a |
interleukin 12A |
susceptibility |
ISO |
associated with hepatitis C;DNA:SNP:3'UTR: rs568408( G>A)(human) associated with hepatitis B; DNA:SNP, haplotype:3′UTR :rs568408(human) |
RGD |
PMID:27819525 PMID:26631030 PMID:20521253 |
RGD:25440490, RGD:25440501, RGD:25440491 |
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il15ra |
interleukin 15 receptor subunit alpha |
disease_progression |
ISO |
mRNA:increased expression:liver (human) |
RGD |
PMID:35693827 |
RGD:153344586 |
NCBI chr17:66,802,300...66,831,973
Ensembl chr17:66,802,334...66,832,278
|
|
G |
Il18 |
interleukin 18 |
severity disease_progression susceptibility |
ISO |
associated with hepatitis C;DNA:SNPs, haplotype:promoter:-607C>A, -137G>C(human) associated with hepatitis B, chronic;DNA:SNP:promoter:-607C>A(human) DNA:SNP:promoter:-137G>C(rs187238)(human) |
RGD |
PMID:29341496 PMID:27470888 PMID:27429592 PMID:26893476 |
RGD:14695526, RGD:14696663, RGD:14695540, RGD:11538094 |
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il18r1 |
interleukin 18 receptor 1 |
|
ISO |
mRNA:decreased expression:liver |
RGD |
PMID:26893476 PMID:26893476 |
RGD:11538094, RGD:11538094 |
NCBI chr 9:42,727,416...42,760,971
Ensembl chr 9:42,727,869...42,760,715
|
|
G |
Il1b |
interleukin 1 beta |
susceptibility |
ISO |
DNA:polymorphism:promoter:-31T>C (human) |
RGD |
PMID:21653279 |
RGD:7401222 |
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rap |
interleukin 1 receptor accessory protein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr11:74,062,999...74,199,530
Ensembl chr11:74,070,304...74,199,530
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Il2 |
interleukin 2 |
treatment |
ISO |
|
RGD |
PMID:10933975 PMID:9449371 |
RGD:8693323, RGD:14747035 |
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il21 |
interleukin 21 |
|
ISO |
associated with hepatitis B;DNA:SNPS, haplotype:(rs13143866, rs2221903, rs907715) (human) |
RGD |
PMID:25892873 |
RGD:127285359 |
NCBI chr 2:120,117,105...120,127,012
Ensembl chr 2:120,119,444...120,126,996
|
|
G |
Il6 |
interleukin 6 |
disease_progression treatment |
ISO |
CTD Direct Evidence: marker/mechanism mRNA,protein:increased expression:liver, blood serum (mouse) DNA:SNP: :rs2069852 (human) |
CTD RGD |
PMID:17615358 PMID:20818158 PMID:26297436 PMID:27022031 PMID:26569409 PMID:27368337 More...
|
RGD:11344640, RGD:14975289 |
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il6st |
interleukin 6 cytokine family signal transducer |
|
IEP |
|
RGD |
PMID:15780071 |
RGD:1626706 |
NCBI chr 2:44,065,979...44,106,255
Ensembl chr 2:44,066,130...44,109,936
|
|
G |
Ing3 |
inhibitor of growth family, member 3 |
treatment |
IDA |
|
RGD |
PMID:25156538 |
RGD:9587823 |
NCBI chr 4:50,477,954...50,505,168
Ensembl chr 4:50,477,962...50,503,715
|
|
G |
Inmt |
indolethylamine N-methyltransferase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 4:84,318,197...84,322,493
Ensembl chr 4:84,318,197...84,322,493
|
|
G |
Inpp4b |
inositol polyphosphate-4-phosphatase type II B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29415082 |
|
NCBI chr19:25,920,189...26,670,085
Ensembl chr19:25,925,358...26,280,634
|
|
G |
Ins1 |
insulin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
|
ISO |
associated with Chronic Hepatitis C;mRNA:decreased expression:liver (human) |
RGD |
PMID:33132693 |
RGD:150340613 |
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Insr |
insulin receptor |
|
IEP IMP |
mRNA, protein:increased expression:liver (human, rat) human cells in a mouse model |
RGD |
PMID:23633480 PMID:29610518 |
RGD:9685423, RGD:14700930 |
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Iqgap1 |
IQ motif containing GTPase activating protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20977743 |
|
NCBI chr 1:134,679,581...134,769,776
Ensembl chr 1:134,679,586...134,769,755
|
|
G |
Iqgap2 |
IQ motif containing GTPase activating protein 2 |
|
ISO ISS |
CTD Direct Evidence: marker/mechanism OMIM:114550 |
CTD MouseDO |
PMID:20977743 |
|
NCBI chr 2:26,894,836...27,170,270
Ensembl chr 2:26,894,825...27,170,279
|
|
G |
Iqgap3 |
IQ motif containing GTPase activating protein 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 2:173,542,151...173,583,956
Ensembl chr 2:173,542,110...173,583,956
|
|
G |
Irf2 |
interferon regulatory factor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22561517 |
|
NCBI chr16:45,439,215...45,550,054
Ensembl chr16:45,439,225...45,550,024
|
|
G |
Irs1 |
insulin receptor substrate 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:1311924 PMID:23958494 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Irs2 |
insulin receptor substrate 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16127164 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28919514 |
|
NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435
|
|
G |
Itih3 |
inter-alpha trypsin inhibitor, heavy chain 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19363144 |
|
NCBI chr16:6,101,922...6,117,154
Ensembl chr16:6,101,930...6,116,924
|
|
G |
Itih4 |
inter-alpha-trypsin inhibitor heavy chain 4 |
disease_progression |
ISO |
associated with hepatitis B;protein:decreased expression:serum |
RGD |
PMID:24836184 |
RGD:40903002 |
NCBI chr16:6,080,539...6,095,710
Ensembl chr16:6,080,539...6,095,708
|
|
G |
Jag1 |
jagged canonical Notch ligand 1 |
|
ISO |
protein:increased expression:liver |
RGD |
PMID:30660174 |
RGD:14694832 |
NCBI chr 3:124,406,783...124,442,220
Ensembl chr 3:124,406,794...124,442,209
|
|
G |
Jak1 |
Janus kinase 1 |
|
ISO |
|
RGD |
PMID:23788652 |
RGD:150524353 |
NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926
|
|
G |
Jak2 |
Janus kinase 2 |
severity treatment ameliorates exacerbates |
IEP ISO |
mRNA:decreased expression:liver (human) L-JAK2 KO associated with Diseases of the Aged and non-alcoholic fatty liver disease protein:increased phosphorylation:liver (mouse) protein:increased phosphorylation:liver (human) |
RGD |
PMID:25420511 PMID:29486150 PMID:28100771 PMID:31393852 PMID:22821478 PMID:22392353 More...
|
RGD:18182928, RGD:127285672, RGD:127285675, RGD:127285655, RGD:127285621, RGD:125097525 |
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Jdp2 |
Jun dimerization protein 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20214788 |
|
NCBI chr 6:105,261,619...105,302,386
Ensembl chr 6:105,261,373...105,301,485
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20214788 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
|
ISO |
associated with HBV;protein:increased expression:liver (human) |
RGD |
PMID:15927205 |
RGD:153297768 |
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
severity |
ISO |
protein:decreased expression:liver (human) |
RGD |
PMID:23643089 |
RGD:9590314 |
NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064
|
|
G |
Kbtbd11 |
kelch repeat and BTB domain containing 11 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr16:74,618,291...74,638,010
Ensembl chr16:74,615,792...74,637,736
|
|
G |
Kcnh1 |
potassium voltage-gated channel subfamily H member 1 |
|
ISO |
protein:increased expression:liver (human) |
RGD |
PMID:17022810 |
RGD:9693723 |
NCBI chr13:103,722,140...104,024,762
Ensembl chr13:103,722,245...104,024,740
|
|
G |
Kcnn2 |
potassium calcium-activated channel subfamily N member 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr18:37,817,966...38,258,347
Ensembl chr18:37,817,957...38,258,347
|
|
G |
Kdm1a |
lysine demethylase 1A |
severity |
ISO |
mRNA, protein:increased expression:liver (human) |
RGD |
PMID:23236241 |
RGD:9681002 |
NCBI chr 5:148,782,976...148,838,319
Ensembl chr 5:148,782,976...148,838,319
|
|
G |
Kdm3a |
lysine demethylase 3A |
|
ISO |
mRNA:increased expression:liver (human) |
RGD |
PMID:21607773 |
RGD:9590222 |
NCBI chr 4:103,630,907...103,675,073
Ensembl chr 4:103,630,908...103,675,073
|
|
G |
Kdm5c |
lysine demethylase 5C |
exacerbates |
ISO |
protein:increased expression:liver (human) |
RGD |
PMID:26503415 |
RGD:11530160 |
NCBI chr X:21,345,459...21,387,045
Ensembl chr X:21,345,481...21,381,870
|
|
G |
Kdm6a |
lysine demethylase 6A |
ameliorates |
ISO |
human cells in a mouse model |
RGD |
PMID:32765772 |
RGD:150429729 |
NCBI chr X:4,337,466...4,477,100
Ensembl chr X:4,337,750...4,477,062
|
|
G |
Kdm8 |
lysine demethylase 8 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 1:180,013,969...180,028,829
Ensembl chr 1:180,020,656...180,028,841
|
|
G |
Kdr |
kinase insert domain receptor |
treatment disease_progression |
ISO |
DNA:SNPs: :rs1870377, rs2071559, rs2305948 (human) associated with alcoholic liver cirrhosis;DNA:SNP: :1416A>T (human) protein:decreased expression:liver protein:increased expression:liver |
RGD |
PMID:25182707 PMID:24445728 PMID:23660204 PMID:25333267 PMID:19177438 |
RGD:126848806, RGD:126848814, RGD:126848813, RGD:126848812, RGD:126848810 |
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Kif11 |
kinesin family member 11 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 1:235,124,371...235,176,760
Ensembl chr 1:235,124,316...235,176,766
|
|
G |
Kif14 |
kinesin family member 14 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr13:47,926,975...47,990,598
Ensembl chr13:47,927,044...47,989,164
|
|
G |
Kif15 |
kinesin family member 15 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 8:122,601,888...122,672,750
Ensembl chr 8:122,601,897...122,672,750
|
|
G |
Kif18a |
kinesin family member 18A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 3:95,764,388...95,824,756
Ensembl chr 3:95,764,388...95,824,582
|
|
G |
Kif18b |
kinesin family member 18B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr10:87,870,424...87,889,895
Ensembl chr10:87,870,428...87,889,850
|
|
G |
Kif1b |
kinesin family member 1B |
severity susceptibility |
ISO |
mRNA, protein:decreased expression:liver (human) DNA:snp:intron:c.2537+518A>G (rs17401966) (human) |
RGD |
PMID:26217094 PMID:27122668 |
RGD:11052488, RGD:12738461 |
NCBI chr 5:159,607,697...159,742,778
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Kif20a |
kinesin family member 20A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780
|
|
G |
Kif23 |
kinesin family member 23 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 8:62,397,908...62,425,162
Ensembl chr 8:62,397,948...62,425,072
|
|
G |
Kif2c |
kinesin family member 2C |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 5:130,637,347...130,662,680
Ensembl chr 5:130,637,347...130,662,637
|
|
G |
Kif4a |
kinesin family member 4A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr X:65,721,746...65,824,277
Ensembl chr X:65,721,779...65,824,139
|
|
G |
Kifc1 |
kinesin family member C1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr20:4,998,832...5,017,107
Ensembl chr20:4,999,047...5,017,105
|
|
G |
Klf4 |
KLF transcription factor 4 |
disease_progression treatment |
ISO |
|
RGD |
PMID:22677193 PMID:22677193 |
RGD:14402023, RGD:14402023 |
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Klrb1 |
killer cell lectin like receptor B1 |
disease_progression |
ISO |
mRNA:decreased expression:liver (human) |
RGD |
PMID:35693827 |
RGD:153344586 |
NCBI chr 4:162,456,294...162,474,989
Ensembl chr 4:162,456,294...162,474,989
|
|
G |
Kmt2a |
lysine methyltransferase 2A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22634756 |
|
NCBI chr 8:45,116,763...45,193,320
Ensembl chr 8:45,118,814...45,193,181
|
|
G |
Kmt2b |
lysine methyltransferase 2B |
|
ISO |
DNA:insertions, translocations:intron:IVS3, multiple (human) CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:22634754 PMID:18320596 |
RGD:9588597 |
NCBI chr 1:85,821,700...85,840,987
Ensembl chr 1:85,821,753...85,841,326
|
|
G |
Kmt2c |
lysine methyltransferase 2C |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22634756 |
|
NCBI chr 4:9,620,638...9,834,787
Ensembl chr 4:9,609,627...9,833,539
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
induced |
ISO IAGP |
CTD Direct Evidence: marker/mechanism ClinVar Annotator: match by term: Hepatocellular cancer mRNA,protein:increased expression:liver aflatoxin B1 induced:DNA:transversion,transition mutations:cds: |
CTD ClinVar RGD |
PMID:2278970 PMID:3122217 PMID:11286481 PMID:11563603 PMID:12460918 PMID:15696205 PMID:16361624 PMID:16434492 PMID:16618717 PMID:18316791 PMID:18794081 PMID:19075190 PMID:19114683 PMID:19679400 PMID:20921462 PMID:20921465 PMID:21228335 PMID:22407852 PMID:22722830 PMID:23325582 PMID:25157968 PMID:26619011 PMID:30891959 PMID:29275358 PMID:8446626 More...
|
RGD:14398750, RGD:11568697 |
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Krt18 |
keratin 18 |
|
ISS |
OMIM:114550 |
MouseDO |
|
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
|
|
G |
Lect2 |
leukocyte cell-derived chemotaxin 2 |
ameliorates |
ISO |
protein:increased expression:blood serum (mouse) human cells in mouse model protein:increased expression:blood serum (human) |
RGD |
PMID:24892551 PMID:21394108 PMID:24892551 |
RGD:153323333, RGD:153323335, RGD:153323333 |
NCBI chr17:8,044,759...8,050,983
Ensembl chr17:8,044,759...8,050,983
|
|
G |
Lep |
leptin |
susceptibility severity |
IAGP IEP |
DNA:SNP:enhancer:-2548G>A (rs7799039) (human) protein:increased expression:liver (human) |
RGD |
PMID:28452232 PMID:18573568 |
RGD:15039399, RGD:25330348 |
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lepr |
leptin receptor |
susceptibility |
ISO |
associated with Hepatitis B, Chronic;DNA:SNPs:cds:p.Gln223Arg, Lys109Arg (human) |
RGD |
PMID:23090836 |
RGD:21079466 |
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Letm1 |
leucine zipper and EF-hand containing transmembrane protein 1 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:23392203 |
|
NCBI chr14:76,942,647...76,982,220
Ensembl chr14:76,942,729...76,984,904
|
|
G |
Lifr |
LIF receptor subunit alpha |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 2:56,224,393...56,292,988
Ensembl chr 2:56,250,120...56,286,699
|
|
G |
Lilrb3 |
leukocyte immunoglobulin like receptor B3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 1:69,928,948...69,939,461
Ensembl chr 1:69,928,945...69,939,048
|
|
G |
Loxl3 |
lysyl oxidase-like 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:35841383 |
|
NCBI chr 4:115,540,640...115,556,958
Ensembl chr 4:115,540,685...115,557,466
|
|
G |
Lpar1 |
lysophosphatidic acid receptor 1 |
|
IDA |
|
RGD |
PMID:19000703 |
RGD:2317680 |
NCBI chr 5:73,229,047...73,347,874
Ensembl chr 5:73,229,625...73,369,895
|
|
G |
Lrat |
lecithin retinol acyltransferase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 2:168,264,093...168,273,155
Ensembl chr 2:168,266,877...168,273,619
|
|
G |
Lrp1b |
LDL receptor related protein 1B |
exacerbates |
ISO |
protein:increased expression:liver (human) DNA:mutations:multiple: (human) |
RGD |
PMID:33324588 PMID:33391418 |
RGD:150429776, RGD:150429785 |
NCBI chr 3:24,594,302...26,715,037
Ensembl chr 3:24,594,991...26,715,505
|
|
G |
Lrrc1 |
leucine rich repeat containing 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 8:78,239,897...78,407,347
Ensembl chr 8:78,239,900...78,406,490
|
|
G |
Lrrc56 |
leucine rich repeat containing 56 |
|
ISO |
ClinVar Annotator: match by term: Hepatocellular cancer | ClinVar Annotator: match by term: Hepatocellular carcinoma |
ClinVar |
PMID:11150980 PMID:12835555 PMID:16155195 PMID:16170316 PMID:16329078 PMID:16372351 PMID:16443854 PMID:16835863 PMID:16881968 PMID:16969868 PMID:17054105 PMID:17211612 PMID:17384584 PMID:17412879 PMID:17601930 PMID:17979197 PMID:18039947 PMID:18042262 PMID:18247425 PMID:18978862 PMID:19206176 PMID:19213030 PMID:19255327 PMID:19371735 PMID:19382114 PMID:19669404 PMID:19773371 PMID:20660566 PMID:20859122 PMID:20937837 PMID:20979192 PMID:21438134 PMID:21495179 PMID:21686750 PMID:21834037 PMID:21850009 PMID:22087699 PMID:22256804 PMID:22317973 PMID:22420426 PMID:22495892 PMID:22499344 PMID:22683711 PMID:22726224 PMID:22926243 PMID:23093928 PMID:23096712 PMID:23406027 PMID:23429430 PMID:23751039 PMID:23884457 PMID:24006476 PMID:24033266 PMID:24129065 PMID:24169525 PMID:24224811 PMID:24390138 PMID:24803665 PMID:25157968 PMID:25326635 PMID:25741868 PMID:25815234 PMID:25914166 PMID:26467025 PMID:26619011 PMID:26778095 PMID:27195699 PMID:27283355 PMID:27444071 PMID:27589201 PMID:28027064 PMID:28139825 PMID:28492532 PMID:29493581 PMID:30055033 PMID:30138938 PMID:30191474 PMID:31394527 PMID:31560489 PMID:31564432 PMID:31775759 PMID:32371413 PMID:32732226 PMID:33027564 PMID:33372952 PMID:34008892 PMID:34958143 PMID:168335863 More...
|
|
NCBI chr 1:196,299,843...196,315,170
Ensembl chr 1:196,299,846...196,315,172
|
|
G |
Lrrc59 |
leucine rich repeat containing 59 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chr10:79,572,295...79,586,953
Ensembl chr10:79,572,317...79,602,533
|
|
G |
Lyve1 |
lymphatic vessel endothelial hyaluronan receptor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 1:164,962,872...164,976,309
Ensembl chr 1:164,962,872...164,976,309
|
|
G |
Lztr1 |
leucine zipper like post translational regulator 1 |
|
ISO |
DNA:missense mutation:cds, liver (human) |
RGD |
PMID:28622513 |
RGD:151893487 |
NCBI chr11:83,487,717...83,503,896
Ensembl chr11:83,487,717...83,503,633
|
|
G |
Mad2l1 |
mitotic arrest deficient 2 like 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 4:95,906,692...95,918,885
Ensembl chr 4:95,906,817...95,913,470
|
|
G |
Magec2 |
MAGE family member C2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr X:140,610,610...140,615,484
Ensembl chr X:140,606,825...140,615,471
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
exacerbates |
ISO IEP |
mRNA:increased expression:liver (human) protein:increased expression:liver, cytosol (rat) |
RGD |
PMID:33553243 PMID:9397988 |
RGD:150530475, RGD:150530477 |
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Map2k4 |
mitogen activated protein kinase kinase 4 |
|
ISO |
protein:decreased expression:liver (human) |
RGD |
PMID:32850377 |
RGD:150429765 |
NCBI chr10:50,343,227...50,447,956
Ensembl chr10:50,344,915...50,447,993
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
exacerbates |
ISO |
mRNA:decreased expression:liver (human) |
RGD |
PMID:31310010 |
RGD:150573714 |
NCBI chr 2:43,348,572...43,414,706
Ensembl chr 2:43,350,098...43,414,463
|
|
G |
Map3k8 |
mitogen-activated protein kinase kinase kinase 8 |
ameliorates |
ISO |
|
RGD |
PMID:26560698 |
RGD:11342977 |
NCBI chr17:53,382,908...53,403,216
Ensembl chr17:53,383,131...53,403,216
|
|
G |
Map4k4 |
mitogen-activated protein kinase kinase kinase kinase 4 |
ameliorates treatment severity |
ISO |
human cell line in a mouse model human recombinant gene and cell line in a mouse model |
RGD |
PMID:21196414 PMID:31922225 PMID:27010469 |
RGD:151347673, RGD:151347839, RGD:151347674 |
NCBI chr 9:42,200,708...42,326,708
Ensembl chr 9:42,200,278...42,326,698
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
treatment exacerbates |
ISO |
|
RGD |
PMID:25216638 PMID:23271722 |
RGD:151665347, RGD:151665348 |
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
ameliorates |
ISO |
protein:decreased phosphorylation:liver (human) |
RGD |
PMID:33875785 |
RGD:150340688 |
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapt |
microtubule-associated protein tau |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Marco |
macrophage receptor with collagenous structure |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr13:31,616,278...31,648,521
Ensembl chr13:31,616,278...31,648,521
|
|
G |
Mat1a |
methionine adenosyltransferase 1A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12060674 |
|
NCBI chr16:16,983,084...17,001,284
Ensembl chr16:16,983,022...17,001,274
|
|
G |
Mbl2 |
mannose binding lectin 2 |
severity susceptibility no_association |
ISO |
associated with hepatitis C;DNA:SNP: :221C>G(rs709620)(human) associated with hepatitis B;DNA:SNP:exon: protein:decreased expression:plasma DNA:SNPs:promoter:rs7096206(human) associated with viral hepatitis;DNA:polymorphisms:exon: associated with hepatitis B-related cirrhosis;DNA:SNP: :rs11003123(G>A)(human) |
RGD |
PMID:21733090 PMID:26857650 PMID:27557564 PMID:25787238 PMID:18221301 PMID:27298104 More...
|
RGD:14696813, RGD:14696836, RGD:14696835, RGD:14696833, RGD:14696829, RGD:14696814 |
NCBI chr 1:228,016,439...228,024,736
|
|
G |
Mbtps1 |
membrane-bound transcription factor peptidase, site 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:14563831 |
|
NCBI chr19:47,561,598...47,612,769
Ensembl chr19:47,561,598...47,612,791
|
|
G |
Mbtps2 |
membrane-bound transcription factor peptidase, site 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:14563831 |
|
NCBI chr X:37,410,914...37,461,130
Ensembl chr X:37,410,811...37,464,430
|
|
G |
Mcm10 |
minichromosome maintenance 10 replication initiation factor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr17:73,263,788...73,288,346
Ensembl chr17:73,266,095...73,287,364
|
|
G |
Mcm2 |
minichromosome maintenance complex component 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
susceptibility |
IAGP IEP |
associated with hepatitis B;DNA:SNP:promoter: (rs999885) (human) associated with hepatitis B;miRNA:increased expression:liver (human) |
RGD |
PMID:24416400 PMID:27298561 |
RGD:15042885, RGD:15042853 |
NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063
|
|
G |
Mcm9 |
minichromosome maintenance 9 homologous recombination repair factor |
|
ISS |
OMIM:114550 |
MouseDO |
|
|
NCBI chr20:32,818,219...32,929,577
Ensembl chr20:32,844,951...32,929,600
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
susceptibility |
ISO |
DNA:transversion:promoter:g.-309T>G (human) |
RGD |
PMID:20019189 |
RGD:2317357 |
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Me1 |
malic enzyme 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21147110 |
|
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
|
|
G |
Mecp2 |
methyl CpG binding protein 2 |
|
ISO IEP |
CTD Direct Evidence: marker/mechanism mRNA, protein:increased expression:liver |
CTD RGD |
PMID:26189965 PMID:11844796 |
RGD:2289670 |
NCBI chr X:151,781,177...151,844,687
Ensembl chr X:151,789,930...151,844,689
|
|
G |
Med1 |
mediator complex subunit 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20007298 |
|
NCBI chr10:83,145,538...83,189,260
Ensembl chr10:83,145,568...83,189,299
|
|
G |
Melk |
maternal embryonic leucine zipper kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 5:58,540,393...58,600,562
Ensembl chr 5:58,540,449...58,600,937
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
severity |
IEP ISO |
protein:increased expression:liver (rat) ClinVar Annotator: match by term: Hepatocellular cancer protein:increased expression:liver (human) CTD Direct Evidence: marker/mechanism mRNA:increased expression:liver, carcinoma (human) |
OMIM ClinVar CTD RGD |
PMID:21774103 PMID:21970370 PMID:22703879 PMID:24728327 PMID:25741868 PMID:28259294 PMID:28492532 PMID:29641532 PMID:32045588 PMID:17311762 PMID:29303510 PMID:29303510 PMID:9927037 PMID:17154373 More...
|
RGD:2317495, RGD:152995524, RGD:152995524, RGD:1600123, RGD:2317575 |
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Mfsd2a |
MFSD2 lysolipid transporter A, lysophospholipid |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 5:135,225,801...135,240,744
Ensembl chr 5:135,225,816...135,240,690
|
|
G |
Mill1 |
MHC I like leukocyte 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21499248 |
|
NCBI chr 1:78,372,798...78,398,932
Ensembl chr 1:78,372,802...78,398,930
|
|
G |
Mir106b |
microRNA 106b |
severity disease_progression |
IEP |
miRNA:decreased expression:liver (human) miRNA:increased expression:liver (human) miRNA:increased expression:serum (human) miRNA:increased expression:plasma (human) |
RGD |
PMID:28958640 PMID:31406464 PMID:28611524 PMID:25894380 |
RGD:15042874, RGD:15042877, RGD:15042876, RGD:15042875 |
NCBI chr12:17,043,344...17,043,425
Ensembl chr12:17,043,344...17,043,425
|
|
G |
Mir107 |
microRNA 107 |
treatment onset |
ISO |
RNA:increased expression:liver: RNA:decreased expression:liver: |
RGD |
PMID:30738047 PMID:28079796 PMID:26191213 PMID:27773820 |
RGD:14975277, RGD:14975300, RGD:11066920, RGD:14975278 |
NCBI chr 1:232,337,767...232,337,853
Ensembl chr 1:232,337,767...232,337,853
|
|
G |
Mir122 |
microRNA 122 |
severity |
ISO |
CTD Direct Evidence: marker/mechanism mRNA:decreased expression:blood (human) protein:decreased expression:liver (human) associated with hepatitis B miRNA:decreased expression:liver |
CTD RGD |
PMID:16924677 PMID:27528885 PMID:19584283 PMID:25422324 PMID:25269820 |
RGD:151361113, RGD:151356981, RGD:14401603, RGD:14394424 |
NCBI chr18:58,758,703...58,758,787
|
|
G |
Mir125a |
microRNA 125a |
treatment severity |
ISO |
RNA:increased expression:liver: |
RGD |
PMID:30257386 PMID:29951066 PMID:30257386 |
RGD:21403677, RGD:21403679, RGD:21403677 |
NCBI chr 1:58,677,626...58,677,710
Ensembl chr 1:58,677,626...58,677,710
|
|
G |
Mir127 |
microRNA 127 |
|
ISO |
miRNA:decreased expression:liver (human) |
RGD |
PMID:24854842 |
RGD:152995355 |
NCBI chr 6:128,546,215...128,546,311
Ensembl chr 6:128,546,215...128,546,311
|
|
G |
Mir130b |
microRNA 130b |
severity |
ISO |
miRNA:increased expression:liver |
RGD |
PMID:25387077 |
RGD:14694845 |
NCBI chr11:83,880,163...83,880,244
Ensembl chr11:83,880,163...83,880,244
|
|
G |
Mir133a1 |
microRNA 133a-1 |
disease_progression |
ISO |
mRNA:decreased expression:liver (human) human cells in mouse model |
RGD |
PMID:30086463 PMID:30086463 |
RGD:153344517, RGD:153344517 |
NCBI chr18:1,885,082...1,885,168
|
|
G |
Mir133b |
microRNA 133b |
severity |
ISO |
mRNA:decreased expression:liver(human) |
RGD |
PMID:30391496 |
RGD:155804298 |
NCBI chr 9:23,098,134...23,098,217
Ensembl chr 9:23,098,134...23,098,217
|
|
G |
Mir136 |
microRNA 136 |
exacerbates |
ISO |
RNA:decreased expression:liver (human) |
RGD |
PMID:28849100 |
RGD:153345547 |
NCBI chr 6:128,549,096...128,549,177
Ensembl chr 6:128,549,096...128,549,177
|
|
G |
Mir139 |
microRNA 139 |
|
ISO |
RNA:decreased expression:liver (human) |
RGD |
PMID:30710422 |
RGD:153344549 |
NCBI chr 1:155,878,828...155,878,895
Ensembl chr 1:155,878,825...155,878,902
|
|
G |
Mir145 |
microRNA 145 |
severity |
IEP |
miRNA:decreased expression:liver (human) |
RGD |
PMID:30572504 |
RGD:15039395 |
NCBI chr18:55,099,640...55,099,727
Ensembl chr18:55,099,640...55,099,727
|
|
G |
Mir146a |
microRNA 146a |
sexual_dimorphism susceptibility |
ISO |
associated with hepatitis B;miRNA:SNP:exon: (rs2910164) (human) associated with hepatitis B;miRNA:SNP: (human) |
RGD |
PMID:18711148 PMID:24615520 PMID:24816919 |
RGD:126925148, RGD:126925187, RGD:126925158 |
NCBI chr10:27,848,516...27,848,610
Ensembl chr10:27,848,516...27,848,610
|
|
G |
Mir150 |
microRNA 150 |
|
ISO |
mRNA:decreased expression:liver (human) |
RGD |
PMID:30205391 |
RGD:153344577 |
NCBI chr 1:95,605,024...95,605,108
Ensembl chr 1:95,605,024...95,605,108
|
|
G |
Mir152 |
microRNA 152 |
disease_progression |
ISO |
miRNA:decreased expression:liver |
RGD |
PMID:30967300 PMID:26531720 |
RGD:19165146, RGD:21066331 |
NCBI chr10:81,832,936...81,833,020
Ensembl chr10:81,832,936...81,833,020
|
|
G |
Mir154 |
microRNA 154 |
|
ISO |
RNA:decreased expression:liver (human) |
RGD |
PMID:33195697 |
RGD:152995478 |
NCBI chr 6:128,752,947...128,753,030
Ensembl chr 6:128,752,947...128,753,030
|
|
G |
Mir155 |
microRNA 155 |
disease_progression |
ISO |
associated with hepatitis C;DNA:SNP: :rs767649 (human) miRNA:increased expression:serum miRNA:decreased expression:peripheral blood mononuclear cell |
RGD |
PMID:27035278 PMID:27531892 PMID:29528577 PMID:30710754 PMID:28074870 PMID:27035278 More...
|
RGD:21079433, RGD:25671465, RGD:24922222, RGD:21081523, RGD:21079477, RGD:21079433 |
NCBI chr11:23,774,654...23,774,718
Ensembl chr11:23,774,654...23,774,718
|
|
G |
Mir181c |
microRNA 181c |
|
IEP |
miRNA:decreased expression:liver (human) |
RGD |
PMID:31114379 |
RGD:15042894 |
NCBI chr19:23,983,523...23,983,628
Ensembl chr19:23,983,523...23,983,628
|
|
G |
Mir18a |
microRNA 18a |
severity |
IEP |
miRNA:increased expression:liver (human) associated with Hepatitis C, Chronic;miRNA:increased expression:serum (human) associated with hepatitis B;miRNA:increased expression:liver (human) |
RGD |
PMID:19027010 PMID:29455432 PMID:24975878 PMID:30191950 PMID:30519035 |
RGD:15039398, RGD:15039404, RGD:15039401, RGD:15039389, RGD:15039400 |
NCBI chr15:92,180,765...92,180,860
Ensembl chr15:92,180,765...92,180,860
|
|
G |
Mir193a |
microRNA 193a |
disease_progression exacerbates |
ISO |
miRNA:decreased expression:liver (human) DNA:hypomethylation RNA:increased expression:blood serum (human) |
RGD |
PMID:26263159 PMID:28036298 PMID:32960907 PMID:30710422 |
RGD:11070076, RGD:153344564, RGD:153344563, RGD:153344549 |
NCBI chr10:64,672,343...64,672,454
Ensembl chr10:64,672,343...64,672,454
|
|
G |
Mir195 |
microRNA 195 |
severity |
IEP IMP |
miRNA:decreased expression:liver (human) miRNA:decreased expression:liver (mouse) |
RGD |
PMID:25607636 PMID:25607636 |
RGD:15042896, RGD:15042896 |
NCBI chr10:54,951,838...54,951,924
Ensembl chr10:54,951,838...54,951,924
|
|
G |
Mir196a |
microRNA 196a |
susceptibility |
ISO |
DNA:SNP: : (rs11614913) associated with hepatitis B, chronic; DNA:SNP: : (rs12304647) |
RGD |
PMID:21692953 PMID:24248733 |
RGD:14401594 RGD:14401595 |
NCBI chr 7:134,110,400...134,110,509
Ensembl chr 7:134,110,400...134,110,509
|
|
G |
Mir200b |
microRNA 200b |
treatment disease_progression |
ISO |
mRNA:decreased expression:liver DNA:hypermethylation:promoter |
RGD |
PMID:26919246 PMID:28383782 PMID:28383782 PMID:28383782 PMID:26919246 |
RGD:14928318, RGD:14928322, RGD:14928322, RGD:14928322, RGD:14928318 |
NCBI chr 5:166,649,272...166,649,366
Ensembl chr 5:166,649,272...166,649,366
|
|
G |
Mir20a |
microRNA 20a |
|
ISO |
associated with Human Viral Hepatitis |
RGD |
PMID:30623908 |
RGD:25823145 |
NCBI chr15:92,181,084...92,181,168
Ensembl chr15:92,181,084...92,181,168
|
|
G |
Mir21 |
microRNA 21 |
treatment severity |
ISO |
miRNA:increased expression:liver |
RGD |
PMID:20447717 PMID:21749846 PMID:24963487 |
RGD:14695022, RGD:41404642, RGD:40925952 |
NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348
|
|
G |
Mir212 |
microRNA 212 |
disease_progression ameliorates |
ISO |
|
RGD |
PMID:25965836 PMID:25965836 |
RGD:11054501, RGD:11054501 |
NCBI chr10:60,023,403...60,023,513
Ensembl chr10:60,023,403...60,023,513
|
|
G |
Mir22 |
microRNA 22 |
severity disease_progression |
ISO |
in male; RNA:increased expression:liver: |
RGD |
PMID:23766411 PMID:21750200 PMID:27811373 |
RGD:14700874, RGD:14700876, RGD:14700875 |
NCBI chr10:60,307,039...60,307,133
Ensembl chr10:60,307,039...60,307,133
|
|
G |
Mir221 |
microRNA 221 |
disease_progression treatment |
ISO IEP |
|
RGD |
PMID:25817558 PMID:31801250 PMID:28096271 PMID:28096271 PMID:28096271 PMID:22009537 PMID:29713162 PMID:29713162 More...
|
RGD:11086123, RGD:151893509, RGD:18337275, RGD:18337275, RGD:18337275, RGD:18337273, RGD:18337267, RGD:18337267 |
NCBI chr X:3,429,465...3,429,573
Ensembl chr X:3,429,465...3,429,573
|
|
G |
Mir222 |
microRNA 222 |
disease_progression severity |
ISO |
|
RGD |
PMID:24124720 PMID:20103675 |
RGD:151709003, RGD:151709004 |
NCBI chr X:3,428,904...3,429,006
Ensembl chr X:3,428,904...3,429,006
|
|
G |
Mir223 |
microRNA 223 |
disease_progression |
ISO |
associated with high-fat diet, RNA:increased expression:serum: associated with Chronic Hepatitis B; RNA:decreased expression:serum: associated with Chronic HepatitisC; RNA:decreased expression:serum: |
RGD |
PMID:30964207 PMID:21229610 PMID:24595450 PMID:25391771 PMID:28982915 |
RGD:21408549, RGD:21408591, RGD:21408583, RGD:21408580, RGD:21408578 |
NCBI chr X:61,141,887...61,141,996
Ensembl chr X:61,141,887...61,141,996
|
|
G |
Mir224 |
microRNA 224 |
severity |
IEP |
miRNA:increased expression:liver (human) miRNA:increased expression:plasma (human) associated with hepatitis B;miRNA:increased expression:liver (human) |
RGD |
PMID:23922662 PMID:27462777 PMID:24923856 PMID:23913306 PMID:22459148 |
RGD:18182921, RGD:18182926, RGD:18182924, RGD:18182923, RGD:18182922 |
NCBI chr X:150,065,088...150,065,169
Ensembl chr X:150,065,088...150,065,169
|
|
G |
Mir23a |
microRNA 23a |
|
ISO |
miRNA:increased expression:liver |
RGD |
PMID:22318941 |
RGD:14694846 |
NCBI chr19:23,954,997...23,955,071
Ensembl chr19:23,954,997...23,955,071
|
|
G |
Mir23b |
microRNA 23b |
|
ISO |
DNA:hypermethylation |
RGD |
PMID:28036298 |
RGD:153344564 |
NCBI chr17:1,813,667...1,813,763
Ensembl chr17:1,813,667...1,813,763
|
|
G |
Mir25 |
microRNA 25 |
severity |
IEP |
miRNA:increased expression:liver (human) associated with hepatitis B;miRNA:increased expression:liver (human) associated with hepatitis B;miRNA:increased expression:serum (human) |
RGD |
PMID:30191950 PMID:27298561 PMID:21098710 PMID:24593846 |
RGD:15039389, RGD:15042853, RGD:15042899, RGD:15042897 |
NCBI chr12:17,042,932...17,043,015
Ensembl chr12:17,042,932...17,043,015
|
|
G |
Mir27a |
microRNA 27a |
severity treatment |
ISO |
human cell line in a mouse model human miRNA and cell line in a mouse model |
RGD |
PMID:29143999 PMID:30083261 |
RGD:14696659, RGD:14696660 |
NCBI chr19:23,954,831...23,954,917
Ensembl chr19:23,954,831...23,954,917
|
|
G |
Mir29a |
microRNA 29a |
severity |
ISO |
associated with hepatitis B;miRNA:increased expression:liver (human) |
RGD |
PMID:23285022 |
RGD:15042850 |
NCBI chr 4:59,650,608...59,650,695
|
|
G |
Mir31 |
microRNA 31 |
severity |
ISO IEP |
RNA:decreased expression:liver (human) miRNA:decreased expression:liver (rat) miRNA:decreased expression:liver (human) |
RGD |
PMID:28623129 PMID:25797269 PMID:25797269 |
RGD:152998991, RGD:11085965, RGD:11085965 |
NCBI chr 5:103,599,038...103,599,143
|
|
G |
Mir340-1 |
microRNA 340-1 |
|
ISO |
miRNA:decreased expression:liver |
RGD |
PMID:27998770 |
RGD:18936991 |
NCBI chr10:34,393,568...34,393,665
Ensembl chr10:34,393,568...34,393,665
|
|
G |
Mir34a |
microRNA 34a |
treatment |
ISO |
human cell line in a mouse model miRNA:decreased expression:liver |
RGD |
PMID:25217526 PMID:29328457 |
RGD:14694835, RGD:14694836 |
NCBI chr 5:160,533,002...160,533,103
Ensembl chr 5:160,533,002...160,533,103
|
|
G |
Mir411 |
microRNA 411 |
disease_progression |
ISO |
mRNA:decreased expression:liver (human) |
RGD |
PMID:30086881 |
RGD:152999437 |
NCBI chr 6:128,723,189...128,723,264
Ensembl chr 6:128,723,184...128,723,279
|
|
G |
Mir455 |
microRNA 455 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:35286011 |
|
NCBI chr 5:76,689,313...76,689,390
Ensembl chr 5:76,689,313...76,689,390
|
|
G |
Mir494 |
microRNA 494 |
disease_progression |
ISO |
|
RGD |
PMID:25820676 |
RGD:155900754 |
NCBI chr 6:128,728,710...128,728,792
Ensembl chr 6:128,728,709...128,728,793
|
|
G |
Mir615 |
microRNA 615 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22819824 |
|
NCBI chr 7:134,151,887...134,151,978
Ensembl chr 7:134,151,887...134,151,978
|
|
G |
Mir665 |
microRNA 665 |
disease_progression |
ISO |
mRNA:increased expression:liver (human) associated with metastasis; human cells in mouse model |
RGD |
PMID:30237408 PMID:30237408 |
RGD:151361293, RGD:151361293 |
NCBI chr 6:128,539,440...128,539,533
Ensembl chr 6:128,539,440...128,539,533
|
|
G |
Mir93 |
microRNA 93 |
severity |
IEP |
associated with hepatitis B;miRNA:increased expression:liver (human) |
RGD |
PMID:27298561 PMID:28592130 |
RGD:15042853, RGD:15042900 |
NCBI chr12:17,043,135...17,043,221
Ensembl chr12:17,043,135...17,043,221
|
|
G |
Mir96 |
microRNA 96 |
severity |
IEP |
miRNA:increased expression:liver (human) |
RGD |
PMID:28892647 PMID:25813403 |
RGD:15042901, RGD:15042902 |
NCBI chr 4:58,788,411...58,788,516
Ensembl chr 4:58,788,411...58,788,516
|
|
G |
Mirlet7c1 |
microRNA let-7c-1 |
|
ISO |
miRNA:decreased expression:liver |
RGD |
PMID:22289550 |
RGD:14695021 |
NCBI chr11:16,201,163...16,201,256
Ensembl chr11:16,201,158...16,201,265
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mlxipl |
MLX interacting protein-like |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21147110 |
|
NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112
|
|
G |
Mme |
membrane metallo-endopeptidase |
|
IEP |
|
RGD |
PMID:8302012 |
RGD:13801035 |
NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:33010264 |
|
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20084675 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:20084675 PMID:21681821 |
RGD:8547864 |
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mogat2 |
monoacylglycerol O-acyltransferase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 1:153,521,813...153,545,756
Ensembl chr 1:153,521,815...153,545,756
|
|
G |
Mpl |
MPL proto-oncogene, thrombopoietin receptor |
|
ISO |
human cells in mouse model |
RGD |
PMID:23157389 |
RGD:126925755 |
NCBI chr 5:131,973,895...131,987,472
Ensembl chr 5:131,973,895...131,986,797
|
|
G |
Mpo |
myeloperoxidase |
disease_progression susceptibility |
ISO |
CTD Direct Evidence: marker/mechanism associated with liver cirrhosis with Hepatitis C;DNA:SNP:promoter:-463G>A(human) associated with liver cirrhosis; DNA:SNP:promoter:-463G>A( rs2333227)(human) |
CTD RGD |
PMID:19731237 PMID:21907168 PMID:19731237 |
RGD:27095879, RGD:26923907 |
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mro |
maestro |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr18:67,450,186...67,467,593
Ensembl chr18:67,450,595...67,467,044
|
|
G |
Msh3 |
mutS homolog 3 |
|
ISO |
ClinVar Annotator: match by term: Hepatocellular cancer |
ClinVar |
PMID:28492532 |
|
NCBI chr 2:23,444,326...23,585,777
|
|
G |
Msh5 |
mutS homolog 5 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr20:3,773,867...3,793,337
Ensembl chr20:3,776,942...3,793,336
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
|
IAGP |
|
RGD |
PMID:2548155 |
RGD:2302301 |
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt-nd5 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5 |
|
IEP |
mRNA:increased expression:liver |
RGD |
PMID:2507335 |
RGD:2302316 |
NCBI chr MT:11,736...13,565
Ensembl chr MT:11,736...13,565
|
|
G |
Mt1 |
metallothionein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17363595 PMID:19363144 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049
|
|
G |
Mt1-ps3 |
metallothionein 1, pseudogene 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr17:74,786,652...74,787,040
Ensembl chr17:74,786,654...74,787,135
|
|
G |
Mt2A |
metallothionein 2A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17363595 PMID:28284560 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mtbp |
MDM2 binding protein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29765550 |
|
NCBI chr 7:86,973,215...87,055,775
Ensembl chr 7:86,973,069...87,050,827
|
|
G |
Mtdh |
metadherin |
treatment |
ISO |
human cells in a mouse model |
RGD |
PMID:26351209 |
RGD:11096879 |
NCBI chr 7:65,306,464...65,365,647
Ensembl chr 7:65,306,400...65,364,413
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
|
IEP |
mRNA:increased expression:liver |
RGD |
PMID:3878730 |
RGD:2302305 |
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Mthfr |
methylenetetrahydrofolate reductase |
susceptibility onset disease_progression |
ISO |
DNA:SNP,haplotype: :677C>T, 1298A>C(human) DNA:SNPs: :677C>T, 1298A>C(human) DNA:SNP: :1298A>C(human) DNA:SNP: :677C>T(human) |
RGD |
PMID:17503006 PMID:17659576 PMID:19035314 PMID:23996892 |
RGD:14696703, RGD:14696708, RGD:14696707, RGD:14696704 |
NCBI chr 5:158,465,248...158,484,999
Ensembl chr 5:158,465,296...158,483,797
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
severity |
ISO |
CTD Direct Evidence: marker/mechanism mRNA, protein:increased expression:liver (human) |
CTD RGD |
PMID:21147110 PMID:25371154 |
RGD:152995471 |
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mtrr |
5-methyltetrahydrofolate-homocysteine methyltransferase reductase |
susceptibility |
ISO |
DNA:SNP: :66A>G(human) |
RGD |
PMID:19035314 |
RGD:14696707 |
NCBI chr 1:34,866,991...34,899,425
Ensembl chr 1:34,867,089...34,899,425
|
|
G |
Mug2 |
murinoglobulin 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 4:155,164,061...155,236,894
Ensembl chr 4:155,164,011...155,236,475
|
|
G |
Mvk |
mevalonate kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21147110 |
|
NCBI chr12:42,141,391...42,158,893
Ensembl chr12:42,141,384...42,158,882
|
|
G |
Mybl2 |
MYB proto-oncogene like 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 3:151,705,254...151,733,714
Ensembl chr 3:151,705,288...151,733,708
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
severity treatment |
ISO IEP IDA |
CTD Direct Evidence: marker/mechanism mRNA:increased expression:liver (human) mRNA:increased expression:liver (rat) |
CTD RGD |
PMID:9029167 PMID:12029619 PMID:15565109 PMID:29698666 PMID:21644509 PMID:22434528 PMID:22076107 PMID:22129741 More...
|
RGD:6903288, RGD:7241004, RGD:7240695, RGD:7240567 |
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
exacerbates treatment ameliorates |
ISO IEP |
mRNA:increased expression:liver (human) human gene and cell in a mouse model mouse cell line in a mouse model protein:increased expression:liver (human) human cell line in a mouse model protein, mRNA:decreased expression:liver (human) |
RGD |
PMID:29022910 PMID:24603331 PMID:31074165 PMID:26985932 PMID:31068809 PMID:32144747 PMID:33575076 PMID:17615358 PMID:28370778 More...
|
RGD:150520022, RGD:150530285, RGD:150524334, RGD:150524330, RGD:150524329, RGD:150524327, RGD:150521534, RGD:150521532, RGD:150520169 |
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nat2 |
N-acetyltransferase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Nbn |
nibrin |
|
ISO |
ClinVar Annotator: match by term: Hepatocellular carcinoma |
ClinVar |
PMID:9590180 PMID:9590181 PMID:9620777 PMID:10398434 PMID:10799436 PMID:10848790 PMID:10852373 PMID:11093281 PMID:11279524 PMID:11953735 PMID:12123493 PMID:12505263 PMID:12833396 PMID:12845677 PMID:14973119 PMID:15185344 PMID:15279809 PMID:16033915 PMID:16544999 PMID:17103455 PMID:18606567 PMID:18940477 PMID:19635536 PMID:19908051 PMID:20444919 PMID:22131123 PMID:22293976 PMID:22373003 PMID:22491912 PMID:22941933 PMID:23317186 PMID:24033266 PMID:24113799 PMID:25485873 PMID:25741868 PMID:25980754 PMID:26083025 PMID:26467025 PMID:26822949 PMID:26845104 PMID:27150568 PMID:27616075 PMID:28492532 PMID:28873162 PMID:29368341 PMID:29419426 PMID:30426508 PMID:31173646 PMID:32295079 PMID:33050356 PMID:33471974 PMID:33471991 PMID:33840814 PMID:34072463 PMID:34072659 PMID:34544220 PMID:35309086 More...
|
|
NCBI chr 5:29,459,574...29,494,152
Ensembl chr 5:29,459,457...29,494,150
|
|
G |
Ncapg |
non-SMC condensin I complex, subunit G |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr14:65,403,930...65,432,902
Ensembl chr14:65,404,163...65,432,902
|
|
G |
Ncaph |
non-SMC condensin I complex, subunit H |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 3:114,371,937...114,399,178
Ensembl chr 3:114,371,941...114,399,180
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
exacerbates |
ISO |
|
RGD |
PMID:28273073 PMID:22556267 |
RGD:153002573, RGD:153002576 |
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Ndc80 |
NDC80 kinetochore complex component |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 9:111,407,191...111,440,921
Ensembl chr 9:111,407,191...111,440,924
|
|
G |
Neil3 |
nei-like DNA glycosylase 3 |
disease_progression |
ISO |
CTD Direct Evidence: marker/mechanism mRNA:increased expression:liver (human) |
CTD RGD |
PMID:28284560 PMID:35693827 |
RGD:153344586 |
NCBI chr16:38,359,305...38,418,528
Ensembl chr16:38,359,371...38,418,527
|
|
G |
Nek2 |
NIMA-related kinase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr13:103,405,818...103,419,063
Ensembl chr13:103,405,819...103,419,051
|
|
G |
Nf2 |
NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor |
disease_progression |
ISO |
DNA, protein:SNP, increased expression:intron, liver protein:decreased expression:liver |
RGD |
PMID:29130106 PMID:26443326 PMID:27289045 |
RGD:150530489, RGD:11076529, RGD:150530504 |
NCBI chr14:79,627,399...79,710,709
Ensembl chr14:79,627,399...79,710,667
|
|
G |
Nfe2l1 |
NFE2 like bZIP transcription factor 1 |
|
ISS |
OMIM:114550 |
MouseDO |
|
|
NCBI chr10:81,796,055...81,812,926
Ensembl chr10:81,800,366...81,832,318
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism ClinVar Annotator: match by term: Hepatocellular carcinoma |
CTD ClinVar RGD |
PMID:22561517 PMID:26619011 PMID:29018201 PMID:31546024 |
RGD:21201310 |
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
disease_progression treatment |
ISO IEP |
associated with Chronic Hepatitis B;DNA:insertion/deletion:3'utr: -94ins/delATTG (rs28720239) (human) |
RGD |
PMID:19797428 PMID:25999787 |
RGD:40400751, RGD:152177911 |
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
susceptibility disease_progression |
ISO |
CTD Direct Evidence: therapeutic associated with hepatitis B;DNA:SNP:promoter:-826C>T (rs2233406) (human) associated with Chronic Hepatitis B;DNA:SNPs,haplotype:3'utr,promoter: 826C>T,881A>G (rs2233406,rs3138053) (human) |
CTD RGD |
PMID:22022477 PMID:25223483 PMID:19797428 |
RGD:40902986, RGD:40400751 |
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nkx3-1 |
NK3 homeobox 1 |
treatment |
ISO |
mRNA:decreased expression:liver human gene in a mouse model |
RGD |
PMID:28972178 PMID:28972178 |
RGD:14401599, RGD:14401599 |
NCBI chr15:44,473,851...44,476,443
Ensembl chr15:44,473,851...44,476,441
|
|
G |
Nlrc3 |
NLR family, CARD domain containing 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30081150 |
|
NCBI chr10:11,551,378...11,585,027
Ensembl chr10:11,551,356...11,584,398
|
|
G |
Nlrc5 |
NLR family, CARD domain containing 5 |
|
ISO |
protein:increased expression:liver |
RGD |
PMID:27338800 |
RGD:15003194 |
NCBI chr19:10,477,638...10,581,023
Ensembl chr19:10,477,628...10,562,121
|
|
G |
Nme1 |
NME/NM23 nucleoside diphosphate kinase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21472284 |
|
NCBI chr10:78,907,036...78,929,659
Ensembl chr10:78,906,083...78,916,408
|
|
G |
Nnmt |
nicotinamide N-methyltransferase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 8:48,928,663...48,947,734
Ensembl chr 8:48,933,598...48,946,655
|
|
G |
Nos2 |
nitric oxide synthase 2 |
treatment |
IEP |
|
RGD |
PMID:25999787 |
RGD:152177911 |
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Notch3 |
notch receptor 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 7:11,132,984...11,184,025
Ensembl chr 7:11,133,706...11,184,025
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23811326 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21147110 |
|
NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
|
ISO ISS |
CTD Direct Evidence: marker/mechanism OMIM:114550 intestinally expressed human gene in mouse model mRNA:splice variant(s):liver (human) |
CTD MouseDO RGD |
PMID:23811326 PMID:25496033 PMID:24954587 PMID:23213087 PMID:23811326 |
RGD:14928334, RGD:14928330, RGD:14696796 |
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nras |
NRAS proto-oncogene, GTPase |
disease_progression severity |
ISO |
human gene in mouse model ClinVar Annotator: match by term: Hepatocellular cancer | ClinVar Annotator: match by term: Hepatocellular carcinoma mRNA, protein:increased expression:liver (mouse, human) |
ClinVar RGD |
PMID:1654209 PMID:2278970 PMID:2674680 PMID:3122217 PMID:6587382 PMID:8120410 PMID:10821536 PMID:12460918 PMID:12727991 PMID:14508525 PMID:15899789 PMID:16273091 PMID:16291983 PMID:16434492 PMID:17699718 PMID:18390968 PMID:18633438 PMID:18668139 PMID:18948947 PMID:19075190 PMID:19657110 PMID:19880792 PMID:19966803 PMID:20130576 PMID:20149136 PMID:20179705 PMID:20406486 PMID:20619739 PMID:20736745 PMID:21107323 PMID:21305640 PMID:21576590 PMID:21729679 PMID:21829508 PMID:22407852 PMID:22499344 PMID:22718121 PMID:22761467 PMID:22773810 PMID:23076151 PMID:23392294 PMID:23400451 PMID:23414587 PMID:23515407 PMID:23538902 PMID:23569304 PMID:23614898 PMID:24006476 PMID:24033266 PMID:24148783 PMID:24370118 PMID:24671188 PMID:25157968 PMID:25348872 PMID:25695684 PMID:25741868 PMID:26619011 PMID:26821351 PMID:27050078 PMID:28492532 PMID:28780248 PMID:21993994 PMID:30685691 More...
|
RGD:14696775, RGD:14696793 |
NCBI chr 2:190,582,885...190,593,509
Ensembl chr 2:190,582,918...190,591,626
|
|
G |
Nrg1 |
neuregulin 1 |
disease_progression |
ISO |
associated with hepatitis C;mRNA:altered expression:liver (human mRNA:increased expression:liver (human) |
RGD |
PMID:17393520 PMID:27514687 |
RGD:39456104, RGD:39456110 |
NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884
|
|
G |
Nrp1 |
neuropilin 1 |
disease_progression |
ISO |
protein:decreased expression:liver |
RGD |
PMID:25333267 |
RGD:126848812 |
NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633
|
|
G |
Nuf2 |
NUF2 component of NDC80 kinetochore complex |
disease_progression treatment |
ISO |
CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:28284560 PMID:31933938 PMID:30653265 |
RGD:28912742, RGD:28867240 |
NCBI chr13:81,693,675...81,722,765
Ensembl chr13:81,693,598...81,722,766
|
|
G |
Nusap1 |
nucleolar and spindle associated protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 3:106,603,273...106,633,428
Ensembl chr 3:106,603,289...106,633,624
|
|
G |
Oit3 |
oncoprotein induced transcript 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr20:27,390,113...27,410,692
Ensembl chr20:27,390,113...27,410,692
|
|
G |
Olfml2a |
olfactomedin-like 2A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 3:22,688,590...22,717,917
Ensembl chr 3:22,688,598...22,717,909
|
|
G |
Olfml2b |
olfactomedin-like 2B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr13:82,869,414...82,906,607
Ensembl chr13:82,869,433...82,906,607
|
|
G |
Orc1 |
origin recognition complex, subunit 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 5:123,324,273...123,348,375
Ensembl chr 5:123,324,315...123,348,375
|
|
G |
Otc |
ornithine transcarbamylase |
severity |
ISO |
mRNA:altered expression:liver tumor (human) |
RGD |
PMID:30901224 |
RGD:152995286 |
NCBI chr X:12,453,834...12,529,954
Ensembl chr X:12,453,834...12,566,918
|
|
G |
Pafah1b1 |
platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 |
disease_progression |
ISO |
mRNA,protein:decreased expression:liver: |
RGD |
PMID:21569763 |
RGD:12790589 |
NCBI chr10:59,533,042...59,591,808
Ensembl chr10:59,534,117...59,591,808
|
|
G |
Pamr1 |
peptidase domain containing associated with muscle regeneration 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 3:88,889,061...88,988,615
Ensembl chr 3:88,889,046...88,988,606
|
|
G |
Park7 |
Parkinsonism associated deglycase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21472284 |
|
NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18695907 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pbk |
PDZ binding kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19363144 PMID:28284560 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pclaf |
PCNA clamp associated factor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28284560 |
|
NCBI chr 8:66,420,606...66,432,994
Ensembl chr 8:66,420,587...66,432,994 Ensembl chr 8:66,420,587...66,432,994
|
|
G |
Pcna |
proliferating cell nuclear antigen |
treatment |
IEP |
protein:increased expression:liver: |
RGD |
PMID:23219601 PMID:25999787 |
RGD:10448993, RGD:152177911 |
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pdcd1 |
programmed cell death 1 |
disease_progression |
ISO |
associated with hepatitis B;DNA:SNP: : +8669 A>G (human) |
RGD |
PMID:27034168 PMID:21912640 |
RGD:40818257, RGD:41410800 |
NCBI chr 9:94,418,786...94,431,945
Ensembl chr 9:94,418,791...94,431,937
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20506153 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pdgfrl |
platelet-derived growth factor receptor-like |
|
ISO |
CTD Direct Evidence: marker/mechanism ClinVar Annotator: match by term: Hepatocellular carcinoma |
OMIM CTD ClinVar |
PMID:7898930 |
|
NCBI chr16:51,347,929...51,407,850
Ensembl chr16:51,347,948...51,407,850
|
|
G |
Pdia3 |
protein disulfide isomerase family A, member 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21472284 |
|
NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28003426 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pfas |
phosphoribosylformylglycinamidine synthase |
|
IEP |
protein:increased activity:hepatoma (rat) |
RGD |
PMID:6722784 |
RGD:5135276 |
NCBI chr10:53,690,301...53,711,811
Ensembl chr10:53,691,626...53,708,420
|
|
G |
Pfn2 |
profilin 2 |
disease_progression |
ISO |
mRNA:increased expression:liver (human) |
RGD |
PMID:35693827 |
RGD:153344586 |
NCBI chr 2:142,067,102...142,072,938
Ensembl chr 2:142,067,104...142,072,938
|
|
G |
| |